{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:43:06Z","timestamp":1793158986891,"version":"4.5.0"},"reference-count":257,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Neurobiol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s10571-023-01349-1","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T09:02:11Z","timestamp":1681894931000},"page":"2713-2741","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Phosphodiesterase-4 Inhibition in Parkinson\u2019s Disease: Molecular Insights and Therapeutic Potential"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6225-7029","authenticated-orcid":false,"given":"Dhritiman","family":"Roy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9154-2248","authenticated-orcid":false,"given":"Shivaramakrishnan","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2666-0878","authenticated-orcid":false,"given":"Praveen Thaggikuppe","family":"Krishnamurthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyong","family":"Sola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4540-1073","authenticated-orcid":false,"given":"Emdormi","family":"Rymbai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"key":"1349_CR1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.1034107","author":"H Abdulrahim","year":"2015","unstructured":"Abdulrahim H, Thistleton S, Adebajo AO et al (2015) Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis. Expert Opin Pharmacother. https:\/\/doi.org\/10.1517\/14656566.2015.1034107","journal-title":"Expert Opin Pharmacother"},{"key":"1349_CR2","doi-asserted-by":"publisher","first-page":"9876","DOI":"10.1073\/pnas.0703589104","volume":"104","author":"JH Ahn","year":"2007","unstructured":"Ahn JH, Jee YS, McAvoy T et al (2007) The B\u2033\/PR72 subunit mediates Ca2+-dependent dephosphorylation of DARPP-32 by protein phosphatase 2A. Proc Natl Acad Sci USA 104:9876\u20139881. https:\/\/doi.org\/10.1073\/pnas.0703589104","journal-title":"Proc Natl Acad Sci USA"},{"key":"1349_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24815","author":"A Aldrich","year":"2016","unstructured":"Aldrich A, Bosch ME, Fallet R et al (2016) Efficacy of phosphodiesterase-4 inhibitors in juvenile Batten disease (CLN3). Ann Neurol. https:\/\/doi.org\/10.1002\/ana.24815","journal-title":"Ann Neurol"},{"key":"1349_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.618411","author":"MS Alqahtani","year":"2021","unstructured":"Alqahtani MS, Kazi M, Alsenaidy MA, Ahmad MZ (2021) Advances in oral drug delivery. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2021.618411","journal-title":"Front Pharmacol"},{"key":"1349_CR5","unstructured":"Alvarez R, Sette C, Yang D, et al (1995) Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. Mol Pharmacol"},{"key":"1349_CR6","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M600933200","author":"JP Anderson","year":"2006","unstructured":"Anderson JP, Walker DE, Goldstein JM et al (2006) Phosphorylation of Ser-129 is the dominant pathological modification of \u03b1-synuclein in familial and sporadic lewy body disease. J Biol Chem. https:\/\/doi.org\/10.1074\/jbc.M600933200","journal-title":"J Biol Chem"},{"key":"1349_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2007.08.011","author":"CM Atkins","year":"2007","unstructured":"Atkins CM, Oliva AA, Alonso OF et al (2007) Modulation of the cAMP signaling pathway after traumatic brain injury. Exp Neurol. https:\/\/doi.org\/10.1016\/j.expneurol.2007.08.011","journal-title":"Exp Neurol"},{"key":"1349_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703636","author":"GS Baillie","year":"2000","unstructured":"Baillie GS, MacKenzie SJ, McPhee I, Houslay MD (2000) Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases. Br J Pharmacol. https:\/\/doi.org\/10.1038\/sj.bjp.0703636","journal-title":"Br J Pharmacol"},{"key":"1349_CR9","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.tips.2004.06.008","volume":"25","author":"KH Banner","year":"2004","unstructured":"Banner KH, Trevethick MA (2004) PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease. Trends Pharmacol Sci 25:430\u2013436. https:\/\/doi.org\/10.1016\/j.tips.2004.06.008","journal-title":"Trends Pharmacol Sci"},{"key":"1349_CR10","first-page":"1396","volume":"273","author":"MS Barnette","year":"1995","unstructured":"Barnette MS, Grous M, Cieslinski LB et al (1995) Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site. J Pharmacol Exp Ther 273:1396\u20131402","journal-title":"J Pharmacol Exp Ther"},{"key":"1349_CR11","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/nn.2153","volume":"11","author":"HS Bateup","year":"2008","unstructured":"Bateup HS, Svenningsson P, Kuroiwa M et al (2008) Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat Neurosci 11:932\u2013939. https:\/\/doi.org\/10.1038\/nn.2153","journal-title":"Nat Neurosci"},{"key":"1349_CR12","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.14.10349","author":"MB Beard","year":"2000","unstructured":"Beard MB, Olsen AE, Jones RE et al (2000) UCR1 and UCR2 domains unique to the cAMP-specific phosphodiesterase family form a discrete module via electrostatic interactions. J Biol Chem. https:\/\/doi.org\/10.1074\/jbc.275.14.10349","journal-title":"J Biol Chem"},{"key":"1349_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/nature06022","author":"EJ Bennett","year":"2007","unstructured":"Bennett EJ, Shaler TA, Woodman B et al (2007) Global changes to the ubiquitin system in Huntington\u2019s disease. Nature. https:\/\/doi.org\/10.1038\/nature06022","journal-title":"Nature"},{"key":"1349_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2005.12.003","author":"R Betarbet","year":"2006","unstructured":"Betarbet R, Canet-Aviles RM, Sherer TB et al (2006) Intersecting pathways to neurodegeneration in Parkinson\u2019s disease: effects of the pesticide rotenone on DJ-1, \u03b1-synuclein, and the ubiquitin-proteasome system. Neurobiol Dis. https:\/\/doi.org\/10.1016\/j.nbd.2005.12.003","journal-title":"Neurobiol Dis"},{"key":"1349_CR15","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1999.0720112.x","author":"NR Bhat","year":"1999","unstructured":"Bhat NR, Zhang P (1999) Hydrogen peroxide activation of multiple mitogen-activated protein kinases in an oligodendrocyte cell line: role of extracellular signal- regulated kinase in hydrogen peroxide-induced cell death. J Neurochem. https:\/\/doi.org\/10.1046\/j.1471-4159.1999.0720112.x","journal-title":"J Neurochem"},{"key":"1349_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105078","author":"A Bhat","year":"2020","unstructured":"Bhat A, Ray B, Mahalakshmi AM et al (2020) Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders. Pharmacol Res. https:\/\/doi.org\/10.1016\/j.phrs.2020.105078","journal-title":"Pharmacol Res"},{"key":"1349_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/45251","author":"JA Bibb","year":"1999","unstructured":"Bibb JA, Snyder GL, Nishi A et al (1999) Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature. https:\/\/doi.org\/10.1038\/45251","journal-title":"Nature"},{"key":"1349_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2020.112692","author":"SS Bilge","year":"2020","unstructured":"Bilge SS, G\u00fcnaydin C, \u00d6nger ME et al (2020) Neuroprotective action of agmatine in rotenone-induced model of Parkinson\u2019s disease: role of BDNF\/cREB and ERK pathway. Behav Brain Res. https:\/\/doi.org\/10.1016\/j.bbr.2020.112692","journal-title":"Behav Brain Res"},{"key":"1349_CR19","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.tips.2019.10.006","volume":"40","author":"A Blokland","year":"2019","unstructured":"Blokland A, Heckman P, Vanmierlo T et al (2019a) Phosphodiesterase type 4 inhibition in CNS diseases. Trends Pharmacol Sci 40:971\u2013985. https:\/\/doi.org\/10.1016\/j.tips.2019.10.006","journal-title":"Trends Pharmacol Sci"},{"key":"1349_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.neurobiolaging.2019.01.014","volume":"77","author":"A Blokland","year":"2019","unstructured":"Blokland A, Van Duinen MA, Sambeth A et al (2019b) Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study. Neurobiol Aging 77:37\u201343. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2019.01.014","journal-title":"Neurobiol Aging"},{"key":"1349_CR21","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.3390\/ijms19102973","volume":"19","author":"A Bohush","year":"2018","unstructured":"Bohush A, Niewiadomska G, Filipek A (2018) Role of mitogen activated protein kinase signaling in Parkinson\u2019s disease. Int J Mol Sci 19:2973. https:\/\/doi.org\/10.3390\/ijms19102973","journal-title":"Int J Mol Sci"},{"key":"1349_CR22","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/0898-6568(94)90018-3","volume":"6","author":"GB Bolger","year":"1994","unstructured":"Bolger GB (1994) Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: a diverse family of regulatory enzymes. Cell Signal 6:851\u2013859. https:\/\/doi.org\/10.1016\/0898-6568(94)90018-3","journal-title":"Cell Signal"},{"key":"1349_CR23","doi-asserted-by":"publisher","first-page":"9413","DOI":"10.1016\/s0021-9258(19)38864-7","volume":"265","author":"K Bomsztyk","year":"1990","unstructured":"Bomsztyk K, Toivola B, Emery DW et al (1990) Role of cAMP in interleukin-1-induced \u03ba light chain gene expression in murine B cell line. J Biol Chem 265:9413\u20139417. https:\/\/doi.org\/10.1016\/s0021-9258(19)38864-7","journal-title":"J Biol Chem"},{"key":"1349_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12588","author":"SD Boomkamp","year":"2014","unstructured":"Boomkamp SD, McGrath MA, Houslay MD, Barnett SC (2014) Epac and the high affinity rolipram binding conformer of PDE4 modulate neurite outgrowth and myelination using an in vitro spinal cord injury model. Br J Pharmacol. https:\/\/doi.org\/10.1111\/bph.12588","journal-title":"Br J Pharmacol"},{"key":"1349_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/biology10121355","author":"A Boyd","year":"2021","unstructured":"Boyd A, Aragon IV, Rich J et al (2021) Assessment of pde4 inhibitor-induced hypothermia as a correlate of nausea in mice. Biology (basel). https:\/\/doi.org\/10.3390\/biology10121355","journal-title":"Biology (basel)"},{"key":"1349_CR26","doi-asserted-by":"publisher","first-page":"8911","DOI":"10.1523\/jneurosci.22-20-08911.2002","volume":"22","author":"K Brami-Cherrier","year":"2002","unstructured":"Brami-Cherrier K, Valjent E, Garcia M et al (2002) Dopamine induces a PI3-kinase-independent activation of Akt in striatal neurons: a new route to cAMP response element-binding protein phosphorylation. J Neurosci 22:8911\u20138921. https:\/\/doi.org\/10.1523\/jneurosci.22-20-08911.2002","journal-title":"J Neurosci"},{"key":"1349_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2005.03857.x","author":"S Brecht","year":"2005","unstructured":"Brecht S, Kirchhof R, Chromik A et al (2005) Specific pathophysiological functions of JNK isoforms in the brain. Eur J Neurosci. https:\/\/doi.org\/10.1111\/j.1460-9568.2005.03857.x","journal-title":"Eur J Neurosci"},{"key":"1349_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2005.04190.x","author":"AM Brown","year":"2005","unstructured":"Brown AM, Deuten AY, Colbran RJ (2005) Dopamine depletion alters phosphorylation of striatal proteins in a model of Parkinsonism. Eur J Neurosci. https:\/\/doi.org\/10.1111\/j.1460-9568.2005.04190.x","journal-title":"Eur J Neurosci"},{"key":"1349_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1598","author":"AB Burgin","year":"2010","unstructured":"Burgin AB, Magnusson OT, Singh J et al (2010) Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol. https:\/\/doi.org\/10.1038\/nbt.1598","journal-title":"Nat Biotechnol"},{"key":"1349_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2019.152842","author":"CZ Cai","year":"2019","unstructured":"Cai CZ, Zhou HF, Yuan NN et al (2019) Natural alkaloid harmine promotes degradation of alpha-synuclein via PKA-mediated ubiquitin-proteasome system activation. Phytomedicine. https:\/\/doi.org\/10.1016\/j.phymed.2019.152842","journal-title":"Phytomedicine"},{"key":"1349_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2010.02.006","author":"C Cant\u00f3","year":"2010","unstructured":"Cant\u00f3 C, Jiang LQ, Deshmukh AS et al (2010) Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab. https:\/\/doi.org\/10.1016\/j.cmet.2010.02.006","journal-title":"Cell Metab"},{"key":"1349_CR32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1750-1326-5-42","volume":"5","author":"S Cao","year":"2010","unstructured":"Cao S, Theodore S, Standaert DG (2010) Fcy receptors are required for NF-kB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson\u2019s disease. Mol Neurodegener 5:42. https:\/\/doi.org\/10.1186\/1750-1326-5-42","journal-title":"Mol Neurodegener"},{"key":"1349_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-9-259","author":"S Cao","year":"2012","unstructured":"Cao S, Standaert DG, Harms AS (2012) The gamma chain subunit of Fc receptors is required for alpha-synuclein-induced pro-inflammatory signaling in microglia. J Neuroinflammation. https:\/\/doi.org\/10.1186\/1742-2094-9-259","journal-title":"J Neuroinflammation"},{"key":"1349_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/S0031-6989(83)80017-4","author":"M Casacchia","year":"1983","unstructured":"Casacchia M, Meco G, Castellana F et al (1983) Therapeutic use of a selective cAMP phosphodiesterase inhibitor (Rolipram) in Parkinson\u2019s disease. Pharmacol Res Commun. https:\/\/doi.org\/10.1016\/S0031-6989(83)80017-4","journal-title":"Pharmacol Res Commun"},{"key":"1349_CR35","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M602632200","author":"EM Chalovich","year":"2006","unstructured":"Chalovich EM, Zhu JH, Caltagarone J et al (2006) Functional repression of cAMP response element in 6-hydroxydopamine-treated neuronal cells. J Biol Chem. https:\/\/doi.org\/10.1074\/jbc.M602632200","journal-title":"J Biol Chem"},{"key":"1349_CR36","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/j.1460-2075.1994.tb06355.x","volume":"13","author":"AC Chao","year":"1994","unstructured":"Chao AC, De Sauvage FJ, Dong YJ et al (1994) Activation of intestinal CFTR Cl- channel by heat-stable enterotoxin and guanylin via cAMP-dependent protein kinase. EMBO J 13:1065\u20131072. https:\/\/doi.org\/10.1002\/j.1460-2075.1994.tb06355.x","journal-title":"EMBO J"},{"key":"1349_CR37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.24.9313","author":"CN Chen","year":"1986","unstructured":"Chen CN, Denome S, Davis RL (1986) Molecular analysis of cDNA clones and the corresponding genomic coding sequences of the Drosophila dunce+ gene, the structural gene for cAMP phosphodiesterase. Proc Natl Acad Sci U S A. https:\/\/doi.org\/10.1073\/pnas.83.24.9313","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1349_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0722-7","author":"J Chen","year":"2018","unstructured":"Chen J, Ren Y, Gui C et al (2018a) Phosphorylation of Parkin at serine 131 by p38 MAPK promotes mitochondrial dysfunction and neuronal death in mutant A53T \u03b1-synuclein model of Parkinson\u2019s disease. Cell Death Dis. https:\/\/doi.org\/10.1038\/s41419-018-0722-7","journal-title":"Cell Death Dis"},{"key":"1349_CR39","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.brainresbull.2017.11.010","volume":"137","author":"J Chen","year":"2018","unstructured":"Chen J, Yu H, Zhong J et al (2018b) The phosphodiesterase-4 inhibitor, FCPR16, attenuates ischemia-reperfusion injury in rats subjected to middle cerebral artery occlusion and reperfusion. Brain Res Bull 137:98\u2013106. https:\/\/doi.org\/10.1016\/j.brainresbull.2017.11.010","journal-title":"Brain Res Bull"},{"key":"1349_CR40","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1080\/21655979.2021.1883279","volume":"12","author":"MY Chen","year":"2021","unstructured":"Chen MY, Fan K, Zhao LJ et al (2021) Long non-coding RNA nuclear enriched abundant transcript 1 (NEAT1) sponges microRNA-124-3p to up-regulate phosphodiesterase 4B (PDE4B) to accelerate the progression of Parkinson\u2019s disease. Bioengineered 12:708\u2013719. https:\/\/doi.org\/10.1080\/21655979.2021.1883279","journal-title":"Bioengineered"},{"key":"1349_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2022.154125","author":"J Chen","year":"2022","unstructured":"Chen J, Zhu Q, Cai C et al (2022) \u03b1 -mangostin derivative 4e as a PDE4 inhibitor promote proteasomal degradation of alpha- synuclein in Parkinson \u2019 s disease models through PKA activation. Phytomedicine. https:\/\/doi.org\/10.1016\/j.phymed.2022.154125","journal-title":"Phytomedicine"},{"key":"1349_CR42","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/j.1745-7270.2008.00438.x","volume":"40","author":"X Cheng","year":"2008","unstructured":"Cheng X, Ji Z, Tsalkova T, Mei F (2008) Epac and PKA: a tale of two intracellular cAMP receptors. Acta Biochim Biophys Sin (shanghai) 40:651\u2013662. https:\/\/doi.org\/10.1111\/j.1745-7270.2008.00438.x","journal-title":"Acta Biochim Biophys Sin (shanghai)"},{"key":"1349_CR43","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/(SICI)1096-9861(19990503)407:2<287::AID-CNE9>3.0.CO;2-R","volume":"407","author":"JA Cherry","year":"1999","unstructured":"Cherry JA, Davis RL (1999) Cyclic amp phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect. J Comp Neurol 407:287\u2013301. https:\/\/doi.org\/10.1002\/(SICI)1096-9861(19990503)407:2%3c287::AID-CNE9%3e3.0.CO;2-R","journal-title":"J Comp Neurol"},{"key":"1349_CR44","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M311164200","author":"WS Choi","year":"2004","unstructured":"Choi WS, Eom DS, Han BS et al (2004) Phosphorylation of p38 MAPK induced by oxidative stress is linked to activation of both caspase-8- and -9-mediated apoptotic pathways in dopaminergic neurons. J Biol Chem. https:\/\/doi.org\/10.1074\/jbc.M311164200","journal-title":"J Biol Chem"},{"key":"1349_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2009.11.022","author":"JS Choi","year":"2010","unstructured":"Choi JS, Park C, Jeong JW (2010) AMP-activated protein kinase is activated in Parkinson\u2019s disease models mediated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Biochem Biophys Res Commun. https:\/\/doi.org\/10.1016\/j.bbrc.2009.11.022","journal-title":"Biochem Biophys Res Commun"},{"key":"1349_CR46","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfw117","author":"AB Cholanians","year":"2016","unstructured":"Cholanians AB, Phan AV, Ditzel EJ et al (2016) Arsenic induces accumulation of \u03b1-synuclein: implications for synucleinopathies and neurodegeneration. Toxicol Sci. https:\/\/doi.org\/10.1093\/toxsci\/kfw117","journal-title":"Toxicol Sci"},{"key":"1349_CR47","doi-asserted-by":"publisher","DOI":"10.4161\/adip.21158","author":"JH Chung","year":"2012","unstructured":"Chung JH (2012) Metabolic benefits of inhibiting cAMP-PDEs with resveratrol. Adipocyte. https:\/\/doi.org\/10.4161\/adip.21158","journal-title":"Adipocyte"},{"key":"1349_CR48","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.10.3599","author":"J Colicelli","year":"1989","unstructured":"Colicelli J, Birchmeier C, Michaeli T et al (1989) Isolation and characterization of a mammalian gene encoding a high-affinity cAMP phosphodiesterase. Proc Natl Acad Sci USA. https:\/\/doi.org\/10.1073\/pnas.86.10.3599","journal-title":"Proc Natl Acad Sci USA"},{"key":"1349_CR49","doi-asserted-by":"publisher","first-page":"5493","DOI":"10.1074\/jbc.R200029200","volume":"278","author":"M Conti","year":"2003","unstructured":"Conti M, Richter W, Mehats C et al (2003) Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 278:5493\u20135496. https:\/\/doi.org\/10.1074\/jbc.R200029200","journal-title":"J Biol Chem"},{"key":"1349_CR50","doi-asserted-by":"publisher","first-page":"13729","DOI":"10.1074\/jbc.274.20.13729","volume":"274","author":"JD Corbin","year":"1999","unstructured":"Corbin JD, Francis SH (1999) Cyclic GMP phosphodiesterase-5: target of Sildenafil. J Biol Chem 274:13729\u201313732. https:\/\/doi.org\/10.1074\/jbc.274.20.13729","journal-title":"J Biol Chem"},{"key":"1349_CR51","doi-asserted-by":"publisher","DOI":"10.1021\/cn1001107","author":"CE Crocker","year":"2011","unstructured":"Crocker CE, Khan S, Cameron MD et al (2011) JNK inhibition protects dopamine neurons and provides behavioral improvement in a rat 6-hydroxydopamine model of Parkinson\u2019s disease. ACS Chem Neurosci. https:\/\/doi.org\/10.1021\/cn1001107","journal-title":"ACS Chem Neurosci"},{"key":"1349_CR52","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1038\/cdd.2011.74","volume":"18","author":"RK Dagda","year":"2011","unstructured":"Dagda RK, Gusdon AM, Pien I et al (2011) Mitochondrially localized PKA reverses mitochondrial pathology and dysfunction in a cellular model of Parkinson\u2019s disease. Cell Death Differ 18:1914\u20131923. https:\/\/doi.org\/10.1038\/cdd.2011.74","journal-title":"Cell Death Differ"},{"key":"1349_CR53","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.12494","author":"RK Dagda","year":"2014","unstructured":"Dagda RK, Pien I, Wang R et al (2014) Beyond the mitochondrion: cytosolic PINK1 remodels dendrites through protein kinase A. J Neurochem. https:\/\/doi.org\/10.1111\/jnc.12494","journal-title":"J Neurochem"},{"key":"1349_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/24884","author":"J De Rooij","year":"1998","unstructured":"De Rooij J, Zwartkruis FJT, Verheijen MHG et al (1998) Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature. https:\/\/doi.org\/10.1038\/24884","journal-title":"Nature"},{"key":"1349_CR55","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1080\/00016489.2016.1211320","volume":"137","author":"E Degerman","year":"2017","unstructured":"Degerman E, In\u2019tZandt R, P\u00e5lbrink A et al (2017) Inhibition of phosphodiesterase 3, 4, and 5 induces endolymphatic hydrops in mouse inner ear, as evaluated with repeated 9.4T MRI. Acta Otolaryngol 137:8\u201315. https:\/\/doi.org\/10.1080\/00016489.2016.1211320","journal-title":"Acta Otolaryngol"},{"key":"1349_CR56","doi-asserted-by":"publisher","first-page":"12535","DOI":"10.1523\/JNEUROSCI.1920-10.2010","volume":"30","author":"B Dehay","year":"2010","unstructured":"Dehay B, Bov\u00e9 J, Rodr\u00edguez-Muela N et al (2010) Pathogenic lysosomal depletion in Parkinson\u2019s disease. J Neurosci 30:12535\u201312544. https:\/\/doi.org\/10.1523\/JNEUROSCI.1920-10.2010","journal-title":"J Neurosci"},{"key":"1349_CR57","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.nbd.2006.09.006","volume":"25","author":"Z DeMarch","year":"2007","unstructured":"DeMarch Z, Giamp\u00e0 C, Patassini S et al (2007) Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity. Neurobiol Dis 25:266\u2013273. https:\/\/doi.org\/10.1016\/j.nbd.2006.09.006","journal-title":"Neurobiol Dis"},{"key":"1349_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2014.05.032","author":"HR Der","year":"2014","unstructured":"Der HR, Wiemerslage L, LaBreck CJ et al (2014) The neuroprotective effect of human uncoupling protein 2 (hUCP2) requires cAMP-dependent protein kinase in a toxin model of Parkinson\u2019s disease. Neurobiol Dis. https:\/\/doi.org\/10.1016\/j.nbd.2014.05.032","journal-title":"Neurobiol Dis"},{"key":"1349_CR59","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.15.8772","author":"F Desdouits","year":"1995","unstructured":"Desdouits F, Cohen D, Nairn AC et al (1995a) Phosphorylation of DARPP-32, a dopamine- and cAMP-regulated phosphoprotein, by casein kinase I in vitro and in vivo. J Biol Chem. https:\/\/doi.org\/10.1074\/jbc.270.15.8772","journal-title":"J Biol Chem"},{"key":"1349_CR60","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1073\/pnas.92.7.2682","volume":"92","author":"F Desdouits","year":"1995","unstructured":"Desdouits F, Siciliano JC, Greengard P, Girault JA (1995b) Dopamine- and cAMP-regulated phosphoprotein DARPP-32: phosphorylation of Ser-137 by casein kinase I inhibits dephosphorylation of Thr-34 by calcineurin. Proc Natl Acad Sci USA 92:2682\u20132685. https:\/\/doi.org\/10.1073\/pnas.92.7.2682","journal-title":"Proc Natl Acad Sci USA"},{"key":"1349_CR61","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/01926230500385549","volume":"34","author":"G Dietsch","year":"2006","unstructured":"Dietsch G, DiPalma C, Eyre R et al (2006) Characterization of the inflammatory response to a highly selective PDE4 inhibitor in the rat and the identification of biomarkers that correlate with toxicity. Toxicol Pathol 34:39\u201351. https:\/\/doi.org\/10.1080\/01926230500385549","journal-title":"Toxicol Pathol"},{"key":"1349_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-021-00768-4","author":"W Dong","year":"2021","unstructured":"Dong W, li, Zhong J hong, Chen Y qing, et al (2021a) Roflupram protects against rotenone-induced neurotoxicity and facilitates \u03b1-synuclein degradation in Parkinson\u2019s disease models. Acta Pharmacol Sin. https:\/\/doi.org\/10.1038\/s41401-021-00768-4","journal-title":"Acta Pharmacol Sin"},{"key":"1349_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-98743-w","author":"XL Dong","year":"2021","unstructured":"Dong XL, Wang YH, Xu J, Zhang N (2021b) The protective effect of the PDE-4 inhibitor rolipram on intracerebral haemorrhage is associated with the cAMP\/AMPK\/SIRT1 pathway. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-021-98743-w","journal-title":"Sci Rep"},{"key":"1349_CR64","unstructured":"DrugBank (2005) https:\/\/go.drugbank.com\/"},{"key":"1349_CR65","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1111\/j.1742-4658.2005.04763.x","volume":"272","author":"N Dumaz","year":"2005","unstructured":"Dumaz N, Marais R (2005) Integrating signals between cAMP and the RAS\/RAF\/MEK\/ERK signalling pathways. Based on the anniversary prize of the gesellschaft fur biochemie und molekularbiologie lecture delivered on 5 July 2003 at the special FEBS meeting in brussels. FEBS J 272:3491\u20133504. https:\/\/doi.org\/10.1111\/j.1742-4658.2005.04763.x","journal-title":"FEBS J"},{"key":"1349_CR66","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1002\/mds.28686","volume":"36","author":"R Erro","year":"2021","unstructured":"Erro R, Mencacci NE, Bhatia KP (2021) The emerging role of phosphodiesterases in movement disorders. Mov Disord 36:2225\u20132243. https:\/\/doi.org\/10.1002\/mds.28686","journal-title":"Mov Disord"},{"key":"1349_CR67","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-018-0374-4","author":"H Feng","year":"2019","unstructured":"Feng H, Wang C, He W et al (2019) Roflumilast ameliorates cognitive impairment in APP\/PS1 mice via cAMP\/CREB\/BDNF signaling and anti-neuroinflammatory effects. Metab Brain Dis. https:\/\/doi.org\/10.1007\/s11011-018-0374-4","journal-title":"Metab Brain Dis"},{"key":"1349_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(00)80395-5","author":"S Finkbeiner","year":"1997","unstructured":"Finkbeiner S, Tavazoie SF, Maloratsky A et al (1997) CREB: A major mediator of neuronal neurotrophin responses. Neuron. https:\/\/doi.org\/10.1016\/S0896-6273(00)80395-5","journal-title":"Neuron"},{"key":"1349_CR69","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409713102","author":"F Fornai","year":"2005","unstructured":"Fornai F, Schl\u00fcter OM, Lenzi P et al (2005) Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and \u03b1-synuclein. Proc Natl Acad Sci U S A. https:\/\/doi.org\/10.1073\/pnas.0409713102","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1349_CR70","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1517\/13543776.2013.794789","volume":"23","author":"A Gavald\u00e0","year":"2013","unstructured":"Gavald\u00e0 A, Roberts RS (2013) Phosphodiesterase-4 inhibitors: a review of current developments (2010\u20132012). Expert Opin Ther Pat 23:997\u20131016. https:\/\/doi.org\/10.1517\/13543776.2013.794789","journal-title":"Expert Opin Ther Pat"},{"key":"1349_CR71","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0704908104","author":"A Ghosh","year":"2007","unstructured":"Ghosh A, Roy A, Liu X et al (2007) Selective inhibition of NF-\u03baB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson\u2019s disease. Proc Natl Acad Sci USA. https:\/\/doi.org\/10.1073\/pnas.0704908104","journal-title":"Proc Natl Acad Sci USA"},{"key":"1349_CR72","doi-asserted-by":"publisher","DOI":"10.1002\/glia.22401","author":"M Ghosh","year":"2012","unstructured":"Ghosh M, Garcia-Castillo D, Aguirre V et al (2012) Proinflammatory cytokine regulation of cyclic AMP-phosphodiesterase 4 signaling in microglia in vitro and following CNS injury. Glia. https:\/\/doi.org\/10.1002\/glia.22401","journal-title":"Glia"},{"key":"1349_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/s0021-9258(20)88248-9","author":"JA Girault","year":"1989","unstructured":"Girault JA, Hemmings HC, Williams KR et al (1989) Phosphorylation of DARPP-32, a dopamine- and cAMP-regulated phosphoprotein, by casein kinase II. J Biol Chem. https:\/\/doi.org\/10.1016\/s0021-9258(20)88248-9","journal-title":"J Biol Chem"},{"key":"1349_CR74","doi-asserted-by":"publisher","DOI":"10.1159\/000493228","author":"J Gong","year":"2018","unstructured":"Gong J, Zhang L, Zhang Q et al (2018) Lentiviral vector-mediated SHC3 silencing exacerbates oxidative stress injury in nigral dopamine neurons by regulating the PI3K-AKT-FoxO signaling pathway in rats with Parkinson\u2019s disease. Cell Physiol Biochem. https:\/\/doi.org\/10.1159\/000493228","journal-title":"Cell Physiol Biochem"},{"key":"1349_CR75","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1136\/gutjnl-2019-318712","volume":"68","author":"M Grover","year":"2019","unstructured":"Grover M, Farrugia G, Stanghellini V (2019) Gastroparesis: a turning point in understanding and treatment. Gut 68:2238\u20132250. https:\/\/doi.org\/10.1136\/gutjnl-2019-318712","journal-title":"Gut"},{"key":"1349_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2019.114874","author":"C Gui","year":"2020","unstructured":"Gui C, Ren Y, Chen J et al (2020) p38 MAPK-DRP1 signaling is involved in mitochondrial dysfunction and cell death in mutant A53T \u03b1-synuclein model of Parkinson\u2019s disease. Toxicol Appl Pharmacol. https:\/\/doi.org\/10.1016\/j.taap.2019.114874","journal-title":"Toxicol Appl Pharmacol"},{"key":"1349_CR77","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-17969-3_7","author":"ME Gurney","year":"2011","unstructured":"Gurney ME, Burgin AB, Magnusson OT, Stewart LJ (2011) Small molecule allosteric modulators of phosphodiesterase 4. Handb Exp Pharmacol. https:\/\/doi.org\/10.1007\/978-3-642-17969-3_7","journal-title":"Handb Exp Pharmacol"},{"key":"1349_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2021.105560","author":"L Hang","year":"2021","unstructured":"Hang L, Wang Z, Foo ASC et al (2021) Conditional disruption of AMP kinase in dopaminergic neurons promotes Parkinson\u2019s disease-associated phenotypes in vivo. Neurobiol Dis. https:\/\/doi.org\/10.1016\/j.nbd.2021.105560","journal-title":"Neurobiol Dis"},{"key":"1349_CR79","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyw030","author":"PRA Heckman","year":"2016","unstructured":"Heckman PRA, van Duinen MA, Bollen EPP et al (2016) Phosphodiesterase inhibition and regulation of dopaminergic frontal and striatal functioning: clinical implications. Int J Neuropsychopharmacol. https:\/\/doi.org\/10.1093\/ijnp\/pyw030","journal-title":"Int J Neuropsychopharmacol"},{"key":"1349_CR80","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.bbr.2018.05.017","volume":"350","author":"PRA Heckman","year":"2018","unstructured":"Heckman PRA, Blokland A, Van Goethem NP et al (2018) The mediating role of phosphodiesterase type 4 in the dopaminergic modulation of motor impulsivity. Behav Brain Res 350:16\u201322. https:\/\/doi.org\/10.1016\/j.bbr.2018.05.017","journal-title":"Behav Brain Res"},{"key":"1349_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/310503a0","author":"HC Hemmings","year":"1984","unstructured":"Hemmings HC, Greengard P, Tung HYL, Cohen P (1984) DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature. https:\/\/doi.org\/10.1038\/310503a0","journal-title":"Nature"},{"key":"1349_CR82","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070951","author":"D Hernandez-Baltazar","year":"2013","unstructured":"Hernandez-Baltazar D, Mendoza-Garrido ME, Martinez-Fong D (2013) Activation of GSK-3\u03b2 and caspase-3 occurs in nigral dopamine neurons during the development of apoptosis activated by a striatal injection of 6-hydroxydopamine. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0070951","journal-title":"PLoS ONE"},{"key":"1349_CR83","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev.biochem.67.1.425","volume":"67","author":"A Hershko","year":"1998","unstructured":"Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67:425\u2013479. https:\/\/doi.org\/10.1146\/annurev.biochem.67.1.425","journal-title":"Annu Rev Biochem"},{"key":"1349_CR84","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.4049\/jimmunol.181.3.2196","volume":"181","author":"R Herv\u00e9","year":"2008","unstructured":"Herv\u00e9 R, Schmitz T, Evain-Brion D et al (2008) The PDE4 inhibitor rolipram prevents NF-\u03baB binding activity and proinflammatory cytokine release in human chorionic cells. J Immunol 181:2196\u20132202. https:\/\/doi.org\/10.4049\/jimmunol.181.3.2196","journal-title":"J Immunol"},{"key":"1349_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2006.07.018","author":"EV Hill","year":"2006","unstructured":"Hill EV, Sheppard CL, Cheung YF et al (2006) Oxidative stress employs phosphatidyl inositol 3-kinase and ERK signalling pathways to activate cAMP phosphodiesterase-4D3 (PDE4D3) through multi-site phosphorylation at Ser239 and Ser579. Cell Signal. https:\/\/doi.org\/10.1016\/j.cellsig.2006.07.018","journal-title":"Cell Signal"},{"key":"1349_CR86","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/18.4.893","author":"R Hoffmann","year":"1999","unstructured":"Hoffmann R, Baillie GS, MacKenzie SJ et al (1999) The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at ser579. EMBO J. https:\/\/doi.org\/10.1093\/emboj\/18.4.893","journal-title":"EMBO J"},{"key":"1349_CR87","first-page":"249","volume-title":"Progress in Nucleic Acid Research and Molecular Biology","author":"MD Houslay","year":"2001","unstructured":"Houslay MD (2001) PDE4 cAMP-specific phosphodiesterases. Progress in Nucleic Acid Research and Molecular Biology. Elsevier, Amsterdam, pp 249\u2013315"},{"key":"1349_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/bj20021698","volume":"370","author":"MD Houslay","year":"2003","unstructured":"Houslay MD, Adams DR (2003) PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370:1\u201318. https:\/\/doi.org\/10.1042\/bj20021698","journal-title":"Biochem J"},{"key":"1349_CR89","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/S1359-6446(05)03622-6","volume":"10","author":"MD Houslay","year":"2005","unstructured":"Houslay MD, Schafer P, Zhang KYJ (2005) Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 10:1503\u20131519. https:\/\/doi.org\/10.1016\/S1359-6446(05)03622-6","journal-title":"Drug Discov Today"},{"key":"1349_CR90","doi-asserted-by":"publisher","DOI":"10.1161\/01.res.0000261934.56938.38","author":"MD Houslay","year":"2007","unstructured":"Houslay MD, Baillie GS, Maurice DH (2007) cAMP-specific phosphodiesterase-4 enzymes in the cardiovascular system. Circ Res. https:\/\/doi.org\/10.1161\/01.res.0000261934.56938.38","journal-title":"Circ Res"},{"key":"1349_CR91","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1006\/exnr.2000.7483","volume":"166","author":"DW Howells","year":"2000","unstructured":"Howells DW, Porritt MJ, Wong JYF et al (2000) Reduced BDNF mRNA expression in the Parkinson\u2019s disease substantia nigra. Exp Neurol 166:127\u2013135. https:\/\/doi.org\/10.1006\/exnr.2000.7483","journal-title":"Exp Neurol"},{"key":"1349_CR92","doi-asserted-by":"publisher","DOI":"10.1021\/bi034653e","author":"Q Huai","year":"2003","unstructured":"Huai Q, Colicelli J, Ke H (2003a) The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis. Biochemistry. https:\/\/doi.org\/10.1021\/bi034653e","journal-title":"Biochemistry"},{"key":"1349_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-2126(03)00123-0","author":"Q Huai","year":"2003","unstructured":"Huai Q, Wang H, Sun Y et al (2003b) Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity. Structure. https:\/\/doi.org\/10.1016\/S0969-2126(03)00123-0","journal-title":"Structure"},{"key":"1349_CR94","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1111\/j.1460-9568.1995.tb01041.x","volume":"7","author":"P Hulley","year":"1995","unstructured":"Hulley P, Hartikka J, Abdel\u2019Al S, et al (1995a) Inhibitors of Type IV phosphodiesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo. Eur J Neurosci 7:2431\u20132440. https:\/\/doi.org\/10.1111\/j.1460-9568.1995.tb01041.x","journal-title":"Eur J Neurosci"},{"key":"1349_CR95","unstructured":"Hulley P, Hartikka J, Lubbert H (1995b) Cyclic AMP promotes the survival of dopaminergic neurons in vitro and protects them from the toxic effects of MPP+. J Neural Transm Suppl 217\u2013228"},{"key":"1349_CR96","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.14.7531","author":"S Hunot","year":"1997","unstructured":"Hunot S, Brugg B, Ricard D et al (1997) Nuclear translocation of NF-\u03bab is increased in dopaminergic neurons of patients with Parkinson disease. Proc Natl Acad Sci U S A. https:\/\/doi.org\/10.1073\/pnas.94.14.7531","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1349_CR97","doi-asserted-by":"publisher","DOI":"10.1523\/jneurosci.19-13-05409.1999","author":"S Ivkovic","year":"1999","unstructured":"Ivkovic S, Ehrlich ME (1999) Expression of the striatal DARPP-32\/ARPP-21 phenotype in GABAergic neurons requires neurotrophins in vivo and in vitro. J Neurosci. https:\/\/doi.org\/10.1523\/jneurosci.19-13-05409.1999","journal-title":"J Neurosci"},{"key":"1349_CR98","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.brainres.2015.07.003","volume":"1622","author":"SSL Jabaris","year":"2015","unstructured":"Jabaris SSL, Sumathy H, Girish R et al (2015) Phosphodiesterase-4 inhibitors ameliorates cognitive deficits in deoxycorticosterone acetate induced hypertensive rats via cAMP\/CREB signaling system. Brain Res 1622:279\u2013291. https:\/\/doi.org\/10.1016\/j.brainres.2015.07.003","journal-title":"Brain Res"},{"key":"1349_CR99","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1007\/s00018-005-4533-5","volume":"62","author":"YH Jeon","year":"2005","unstructured":"Jeon YH, Heo Y-S, Kim CM et al (2005) Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development. Cell Mol Life Sci 62:1198\u20131220. https:\/\/doi.org\/10.1007\/s00018-005-4533-5","journal-title":"Cell Mol Life Sci"},{"key":"1349_CR100","doi-asserted-by":"publisher","first-page":"10414","DOI":"10.1074\/jbc.M610857200","volume":"282","author":"HL Ji","year":"2007","unstructured":"Ji HL, Richter W, Namkung W et al (2007) Dynamic regulation of cystic fibrosis transmembrane conductance regulator by competitive interactions of molecular adaptors. J Biol Chem 282:10414\u201310422. https:\/\/doi.org\/10.1074\/jbc.M610857200","journal-title":"J Biol Chem"},{"key":"1349_CR101","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20031662","author":"LA Johnston","year":"2004","unstructured":"Johnston LA, Erdogan S, Cheung YF et al (2004) Expression, intracellular distribution and basis for lack of catalytic activity of the PDE4A7 isoform encoded by the human PDE4A cAMP-specific phosphodiesterase gene. Biochem J. https:\/\/doi.org\/10.1042\/BJ20031662","journal-title":"Biochem J"},{"key":"1349_CR102","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/BF00999494","volume":"4","author":"D Jovanovi\u0107-Mi\u0107i\u0107","year":"1989","unstructured":"Jovanovi\u0107-Mi\u0107i\u0107 D, \u0160trbac M, Krsti\u0107 SK et al (1989) Ablation of the area postrema and emesis. Metab Brain Dis 4:55\u201360. https:\/\/doi.org\/10.1007\/BF00999494","journal-title":"Metab Brain Dis"},{"key":"1349_CR103","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE (2015) Parkinson\u2019s disease. Lancet 386:896\u2013912. https:\/\/doi.org\/10.1016\/S0140-6736(14)61393-3","journal-title":"Lancet"},{"key":"1349_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3901211","author":"H Ke","year":"2004","unstructured":"Ke H (2004) Implications of PDE4 structure on inhibitor selectivity across PDE families. Int J Impot Res. https:\/\/doi.org\/10.1038\/sj.ijir.3901211","journal-title":"Int J Impot Res"},{"key":"1349_CR105","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0709-1","author":"GM Keating","year":"2017","unstructured":"Keating GM (2017) Apremilast: a review in psoriasis and psoriatic arthritis. Drugs. https:\/\/doi.org\/10.1007\/s40265-017-0709-1","journal-title":"Drugs"},{"key":"1349_CR106","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/277093a0","volume":"277","author":"JW Kebabian","year":"1979","unstructured":"Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277:93\u201396","journal-title":"Nature"},{"key":"1349_CR107","doi-asserted-by":"publisher","DOI":"10.22270\/jddt.v6i3.1228","author":"AD Khan","year":"2016","unstructured":"Khan AD, Singh L (2016) Various techniques of bioavailibility enhancement: a review. J Drug Deliv Ther. https:\/\/doi.org\/10.22270\/jddt.v6i3.1228","journal-title":"J Drug Deliv Ther"},{"key":"1349_CR108","first-page":"2733","volume":"8","author":"AA Khan","year":"2013","unstructured":"Khan AA, Mudassir J, Mohtar N, Darwis Y (2013) Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. Int J Nanomedicine 8:2733\u20132744","journal-title":"Int J Nanomedicine"},{"key":"1349_CR109","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jphs.2017.04.002","volume":"134","author":"K Kinoshita","year":"2017","unstructured":"Kinoshita K, Muroi Y, Unno T, Ishii T (2017) Rolipram improves facilitation of contextual fear extinction in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of {Parkinson}\u2019s disease. J Pharmacol Sci 134:55\u201358. https:\/\/doi.org\/10.1016\/j.jphs.2017.04.002","journal-title":"J Pharmacol Sci"},{"key":"1349_CR110","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a008888","author":"C Klein","year":"2012","unstructured":"Klein C, Westenberger A (2012) Genetics of Parkinson\u2019s disease. Cold Spring Harb Perspect Med. https:\/\/doi.org\/10.1101\/cshperspect.a008888","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1349_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2017.01.059","author":"A Kumar","year":"2017","unstructured":"Kumar A, Singh N (2017) Inhibitor of Phosphodiestearse-4 improves memory deficits, oxidative stress, neuroinflammation and neuropathological alterations in mouse models of dementia of Alzheimer\u2019s Type. Biomed Pharmacother. https:\/\/doi.org\/10.1016\/j.biopha.2017.01.059","journal-title":"Biomed Pharmacother"},{"key":"1349_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2007.12.011","author":"HJ Kwak","year":"2008","unstructured":"Kwak HJ, Park KM, Choi HE et al (2008) PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways. Cell Signal. https:\/\/doi.org\/10.1016\/j.cellsig.2007.12.011","journal-title":"Cell Signal"},{"key":"1349_CR113","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.neuropharm.2010.05.004","volume":"59","author":"V Lakics","year":"2010","unstructured":"Lakics V, Karran EH, Boess FG (2010) Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 59:367\u2013374. https:\/\/doi.org\/10.1016\/j.neuropharm.2010.05.004","journal-title":"Neuropharmacology"},{"key":"1349_CR114","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/S0006-8993(01)03023-2","volume":"920","author":"S Lamontagne","year":"2001","unstructured":"Lamontagne S, Meadows E, Luk P et al (2001) Localization of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey. Brain Res 920:84\u201396. https:\/\/doi.org\/10.1016\/S0006-8993(01)03023-2","journal-title":"Brain Res"},{"key":"1349_CR115","doi-asserted-by":"publisher","first-page":"14502","DOI":"10.1021\/acs.jmedchem.0c00797","volume":"63","author":"J Larsen","year":"2020","unstructured":"Larsen J, Lambert M, Pettersson H et al (2020) Discovery and early clinical development of isobutyl 1-[8-Methoxy-5-(1-oxo-3 H-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5- a]pyridin-2-yl]cyclopropanecarboxylate (LEO 39652), a Novel \u201cdual-Soft\u201d PDE4 inhibitor for topical treatment of atopic dermatitis. J Med Chem 63:14502\u201314521. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00797","journal-title":"J Med Chem"},{"key":"1349_CR116","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10495-021-01667-z","volume":"26","author":"M Li","year":"2021","unstructured":"Li M (2021) The role of P53 up-regulated modulator of apoptosis (PUMA) in ovarian development, cardiovascular and neurodegenerative diseases. Apoptosis 26:235\u2013247. https:\/\/doi.org\/10.1007\/s10495-021-01667-z","journal-title":"Apoptosis"},{"key":"1349_CR117","first-page":"85","volume":"30","author":"X Li","year":"2012","unstructured":"Li X, Zhang H, Niu Q, Yuan F (2012) Changes of cdk5, p35 and p53 gene expression levels in arsenic-induced neural cell apoptosis. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 30:85\u201388","journal-title":"Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi"},{"key":"1349_CR118","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01048","author":"H Li","year":"2018","unstructured":"Li H, Zuo J, Tang W (2018) Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2018.01048","journal-title":"Front Pharmacol"},{"key":"1349_CR119","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1021\/acs.jmedchem.0c00060","volume":"63","author":"J Liang","year":"2020","unstructured":"Liang J, Huang YY, Zhou Q et al (2020) Discovery and optimization of \u03b1-mangostin derivatives as novel PDE4 inhibitors for the treatment of vascular dementia. J Med Chem 63:3370\u20133380. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00060","journal-title":"J Med Chem"},{"key":"1349_CR120","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1586\/14789450.4.6.769","volume":"4","author":"K-L Lim","year":"2007","unstructured":"Lim K-L (2007) Ubiquitin\u2013proteasome system dysfunction in Parkinson\u2019s disease: current evidence and controversies. Expert Rev Proteomics 4:769\u2013781. https:\/\/doi.org\/10.1586\/14789450.4.6.769","journal-title":"Expert Rev Proteomics"},{"key":"1349_CR121","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/542383","author":"J Liu","year":"2014","unstructured":"Liu J, Gao J, Tu S et al (2014) Neuroprotective effects of Jitai tablet, a traditional Chinese medicine, on the MPTP-induced acute model of Parkinson\u2019s disease: involvement of the dopamine system. Evid-Based Complement Altern Med. https:\/\/doi.org\/10.1155\/2014\/542383","journal-title":"Evid-Based Complement Altern Med"},{"key":"1349_CR122","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1522332112","author":"S Lokireddy","year":"2015","unstructured":"Lokireddy S, Kukushkin NV, Goldberg AL (2015) cAMP-induced phosphorylation of 26S proteasomes on Rpn6\/PSMD11 enhances their activity and the degradation of misfolded proteins. Proc Natl Acad Sci USA. https:\/\/doi.org\/10.1073\/pnas.1522332112","journal-title":"Proc Natl Acad Sci USA"},{"key":"1349_CR123","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S0969-8051(01)00206-2","volume":"28","author":"CM Lourenco","year":"2001","unstructured":"Lourenco CM, Houle S, Wilson AA, DaSilva JN (2001) Characterization of R-[11C]rolipram for PET imaging of phosphodiesterase-4: in vivo binding, metabolism, and dosimetry studies in rats. Nucl Med Biol 28:347\u2013358. https:\/\/doi.org\/10.1016\/S0969-8051(01)00206-2","journal-title":"Nucl Med Biol"},{"key":"1349_CR124","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-017-0486-6","author":"D Luo","year":"2018","unstructured":"Luo D, Zhao J, Cheng Y et al (2018) N-propargyl caffeamide (PACA) ameliorates dopaminergic neuronal loss and motor dysfunctions in MPTP mouse model of Parkinson\u2019s disease and in MPP+-induced neurons via promoting the conversion of proNGF to NGF. Mol Neurobiol. https:\/\/doi.org\/10.1007\/s12035-017-0486-6","journal-title":"Mol Neurobiol"},{"key":"1349_CR125","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0625-19.2019","author":"S Luo","year":"2019","unstructured":"Luo S, Kang SS, Wang ZH et al (2019) Akt phosphorylates NQO1 and triggers its degradation, abolishing its antioxidative activities in Parkinson\u2019s disease. J Neurosci. https:\/\/doi.org\/10.1523\/JNEUROSCI.0625-19.2019","journal-title":"J Neurosci"},{"key":"1349_CR126","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704743","author":"SJ MacKenzie","year":"2002","unstructured":"MacKenzie SJ, Baillie GS, McPhee I et al (2002) Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in upstream conserved region 1 (UCR1). Br J Pharmacol. https:\/\/doi.org\/10.1038\/sj.bjp.0704743","journal-title":"Br J Pharmacol"},{"key":"1349_CR127","doi-asserted-by":"crossref","unstructured":"Martinez A, Gil C (2013) CHAPTER 12. Phosphodiesterase Inhibitors as a New Therapeutic Approach for the Treatment of Parkinson\u2019s Disease. pp 294\u2013307","DOI":"10.1039\/9781849737357-00294"},{"key":"1349_CR128","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1172\/JCI11916","volume":"107","author":"MP Mattson","year":"2001","unstructured":"Mattson MP, Camandola S (2001) NF-\u03baB in neuronal plasticity and neurodegenerative disorders. J Clin Invest 107:247\u2013254. https:\/\/doi.org\/10.1172\/JCI11916","journal-title":"J Clin Invest"},{"key":"1349_CR129","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrd4228","volume":"13","author":"DH Maurice","year":"2014","unstructured":"Maurice DH, Ke H, Ahmad F et al (2014) Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov 13:290\u2013314. https:\/\/doi.org\/10.1038\/nrd4228","journal-title":"Nat Rev Drug Discov"},{"key":"1349_CR130","doi-asserted-by":"publisher","first-page":"12533","DOI":"10.1096\/fj.202001016RR","volume":"34","author":"W McDonough","year":"2020","unstructured":"McDonough W, Aragon IV, Rich J et al (2020a) PAN-selective inhibition of cAMP-phosphodiesterase 4 (PDE4) induces gastroparesis in mice. FASEB J 34:12533\u201312548. https:\/\/doi.org\/10.1096\/fj.202001016RR","journal-title":"FASEB J"},{"key":"1349_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114158","author":"W McDonough","year":"2020","unstructured":"McDonough W, Rich J, Aragon IV et al (2020b) Inhibition of type 4 cAMP-phosphodiesterases (PDE4s) in mice induces hypothermia via effects on behavioral and central autonomous thermoregulation. Biochem Pharmacol. https:\/\/doi.org\/10.1016\/j.bcp.2020.114158","journal-title":"Biochem Pharmacol"},{"key":"1349_CR132","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2015.240","author":"A Mcgirr","year":"2016","unstructured":"Mcgirr A, Lipina TV, Mun HS et al (2016) Specific inhibition of phosphodiesterase-4B results in anxiolysis and facilitates memory acquisition. Neuropsychopharmacology. https:\/\/doi.org\/10.1038\/npp.2015.240","journal-title":"Neuropsychopharmacology"},{"key":"1349_CR133","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nrd2058","volume":"5","author":"FS Menniti","year":"2006","unstructured":"Menniti FS, Faraci WS, Schmidt CJ (2006) Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov 5:660\u2013670. https:\/\/doi.org\/10.1038\/nrd2058","journal-title":"Nat Rev Drug Discov"},{"key":"1349_CR134","doi-asserted-by":"publisher","DOI":"10.1126\/science.1112915","author":"JK Millar","year":"2005","unstructured":"Millar JK, Pickard BS, Mackie S et al (2005) Genetics: DISC1 and PDE4B are interacting genetic factors in schizoprenia that regulate cAMP signaling. Science. https:\/\/doi.org\/10.1126\/science.1112915","journal-title":"Science"},{"key":"1349_CR135","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/syn.10100","volume":"45","author":"X Mir\u00f3","year":"2002","unstructured":"Mir\u00f3 X, P\u00e9rez-Torres S, Puigdom\u00e8nech P et al (2002) Differential distribution of PDE4D splice variant mRNAs in rat brain suggests association with specific pathways and presynaptical localization. Synapse 45:259\u2013269. https:\/\/doi.org\/10.1002\/syn.10100","journal-title":"Synapse"},{"key":"1349_CR136","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jchemneu.2010.03.004","volume":"40","author":"F Mori","year":"2010","unstructured":"Mori F, P\u00e9rez-Torres S, De Caro R et al (2010) The human area postrema and other nuclei related to the emetic reflex express cAMP phosphodiesterases 4B and 4D. J Chem Neuroanat 40:36\u201342. https:\/\/doi.org\/10.1016\/j.jchemneu.2010.03.004","journal-title":"J Chem Neuroanat"},{"key":"1349_CR137","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.neubiorev.2016.07.010","volume":"68","author":"AA Moustafa","year":"2016","unstructured":"Moustafa AA, Chakravarthy S, Phillips JR et al (2016) Motor symptoms in Parkinson\u2019s disease: a unified framework. Neurosci Biobehav Rev 68:727\u2013740. https:\/\/doi.org\/10.1016\/j.neubiorev.2016.07.010","journal-title":"Neurosci Biobehav Rev"},{"key":"1349_CR138","doi-asserted-by":"publisher","DOI":"10.1186\/s12993-017-0119-2","author":"C Mucignat","year":"2017","unstructured":"Mucignat C, Caretta A (2017) Drug-induced Parkinson\u2019s disease modulates protein kinase A and olfactory marker protein in the mouse olfactory bulb. Behav Brain Funct. https:\/\/doi.org\/10.1186\/s12993-017-0119-2","journal-title":"Behav Brain Funct"},{"key":"1349_CR139","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4011","author":"N Myeku","year":"2016","unstructured":"Myeku N, Clelland CL, Emrani S et al (2016) Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling. Nat Med. https:\/\/doi.org\/10.1038\/nm.4011","journal-title":"Nat Med"},{"key":"1349_CR140","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1210\/endo.137.6.8641200","volume":"137","author":"F Naro","year":"1996","unstructured":"Naro F, Zhang R, Conti M (1996) Developmental regulation of unique adenosine 3\u2032,5\u2032-monophosphate-specific phosphodiesterase variants during rat spermatogenesis. Endocrinology 137:2464\u20132472. https:\/\/doi.org\/10.1210\/endo.137.6.8641200","journal-title":"Endocrinology"},{"key":"1349_CR141","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.neulet.2019.01.026","volume":"699","author":"E Nelissen","year":"2019","unstructured":"Nelissen E, van Goethem NP, Bonassoli VT et al (2019) Validation of the xylazine\/ketamine anesthesia test as a predictor of the emetic potential of pharmacological compounds in rats. Neurosci Lett 699:41\u201346. https:\/\/doi.org\/10.1016\/j.neulet.2019.01.026","journal-title":"Neurosci Lett"},{"key":"1349_CR142","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S0006-3223(02)01405-1","volume":"52","author":"EJ Nestler","year":"2002","unstructured":"Nestler EJ, Gould E, Manji H (2002) Preclinical models: status of basic research in depression. Biol Psychiatry 52:503\u2013528","journal-title":"Biol Psychiatry"},{"key":"1349_CR143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2021.797390","volume":"12","author":"HO Nguyen","year":"2022","unstructured":"Nguyen HO, Schioppa T, Tiberio L et al (2022) The PDE4 inhibitor tanimilast blunts proinflammatory dendritic cell activation by SARS-CoV-2 ssRNAs. Front Immunol 12:1\u201312. https:\/\/doi.org\/10.3389\/fimmu.2021.797390","journal-title":"Front Immunol"},{"key":"1349_CR144","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004201","author":"F Niccolini","year":"2017","unstructured":"Niccolini F, Wilson H, Pagano G et al (2017) Loss of phosphodiesterase 4 in Parkinson disease. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000004201","journal-title":"Neurology"},{"key":"1349_CR145","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/14728222.2017.1279149","volume":"21","author":"A Nishi","year":"2017","unstructured":"Nishi A, Shuto T (2017) Potential for targeting dopamine\/DARPP-32 signaling in neuropsychiatric and neurodegenerative disorders. Expert Opin Ther Targets 21:259\u2013272. https:\/\/doi.org\/10.1080\/14728222.2017.1279149","journal-title":"Expert Opin Ther Targets"},{"key":"1349_CR146","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1254\/jphs.10r01fm","volume":"114","author":"A Nishi","year":"2010","unstructured":"Nishi A, Snyder GL (2010) Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: biochemical and behavioral profiles of phosphodiesterase inhibition in dopaminergic neurotransmission. J Pharmacol Sci 114:6\u201316. https:\/\/doi.org\/10.1254\/jphs.10r01fm","journal-title":"J Pharmacol Sci"},{"key":"1349_CR147","doi-asserted-by":"publisher","first-page":"8147","DOI":"10.1523\/jneurosci.17-21-08147.1997","volume":"17","author":"A Nishi","year":"1997","unstructured":"Nishi A, Snyder GL, Greengard P (1997) Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J Neurosci 17:8147\u20138155. https:\/\/doi.org\/10.1523\/jneurosci.17-21-08147.1997","journal-title":"J Neurosci"},{"key":"1349_CR148","doi-asserted-by":"publisher","first-page":"12840","DOI":"10.1073\/pnas.220410397","volume":"97","author":"A Nishi","year":"2000","unstructured":"Nishi A, Bibb JA, Snyder GL et al (2000) Amplification of dopaminergic signaling by a positive feedback loop. Proc Natl Acad Sci U S A 97:12840\u201312845. https:\/\/doi.org\/10.1073\/pnas.220410397","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1349_CR149","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1007\/s12035-016-0355-8","volume":"55","author":"DN Nthenge-Ngumbau","year":"2018","unstructured":"Nthenge-Ngumbau DN, Mohanakumar KP (2018) Can cyclic nucleotide phosphodiesterase inhibitors be drugs for Parkinson\u2019s disease? Mol Neurobiol 55:822\u2013834. https:\/\/doi.org\/10.1007\/s12035-016-0355-8","journal-title":"Mol Neurobiol"},{"key":"1349_CR150","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2008.00276.x","author":"S Oddo","year":"2008","unstructured":"Oddo S (2008) The ubiquitin-proteasome system in Alzheimer\u2019s disease. J Cell Mol Med. https:\/\/doi.org\/10.1111\/j.1582-4934.2008.00276.x","journal-title":"J Cell Mol Med"},{"key":"1349_CR151","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2009.01.015","author":"B Omar","year":"2009","unstructured":"Omar B, Zmuda-Trzebiatowska E, Manganiello V et al (2009) Regulation of AMP-activated protein kinase by cAMP in adipocytes: roles for phosphodiesterases, protein kinase B, protein kinase A Epac and lipolysis. Cell Signal. https:\/\/doi.org\/10.1016\/j.cellsig.2009.01.015","journal-title":"Cell Signal"},{"key":"1349_CR152","doi-asserted-by":"publisher","DOI":"10.1007\/BF01188438","author":"CC Ouimet","year":"1990","unstructured":"Ouimet CC, Greengard P (1990) Distribution of DARPP-32 in the basal ganglia: an electron microscopic study. J Neurocytol. https:\/\/doi.org\/10.1007\/BF01188438","journal-title":"J Neurocytol"},{"key":"1349_CR153","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1124\/pharmrev.120.000273","volume":"73","author":"D Paes","year":"2021","unstructured":"Paes D, Schepers M, Rombaut B et al (2021) The molecular biology of phosphodiesterase 4 enzymes as pharmacological targets: an interplay of isoforms, conformational states, and inhibitorss. Pharmacol Rev 73:1016\u20131049. https:\/\/doi.org\/10.1124\/pharmrev.120.000273","journal-title":"Pharmacol Rev"},{"key":"1349_CR154","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000368800","volume":"165","author":"CP Page","year":"2014","unstructured":"Page CP (2014) Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol 165:152\u2013164. https:\/\/doi.org\/10.1159\/000368800","journal-title":"Int Arch Allergy Immunol"},{"key":"1349_CR155","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1517\/13543770903313753","volume":"19","author":"L Pag\u00e8s","year":"2009","unstructured":"Pag\u00e8s L, Gavald\u00e0 A, Lehner MD (2009) PDE4 inhibitors: a review of current developments (2005\u20132009). Expert Opin Ther Pat 19:1501\u20131519. https:\/\/doi.org\/10.1517\/13543770903313753","journal-title":"Expert Opin Ther Pat"},{"key":"1349_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2008.04.065","author":"M Pall\u00e0s","year":"2008","unstructured":"Pall\u00e0s M, Pizarro JG, Gutierrez-Cuesta J et al (2008) Modulation of SIRT1 expression in different neurodegenerative models and human pathologies. Neuroscience. https:\/\/doi.org\/10.1016\/j.neuroscience.2008.04.065","journal-title":"Neuroscience"},{"key":"1349_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.01.017","author":"SJ Park","year":"2012","unstructured":"Park SJ, Ahmad F, Philp A et al (2012) Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell. https:\/\/doi.org\/10.1016\/j.cell.2012.01.017","journal-title":"Cell"},{"key":"1349_CR158","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/syn.20114","volume":"55","author":"CA Parker","year":"2005","unstructured":"Parker CA, Matthews JC, Gunn RN et al (2005) Behaviour of [11C]R(-)- and [11C]S(+)-rolipram in vitro and in vivo, and their use as PET radiotracers for the quantificative assay of PDE4. Synapse 55:270\u2013279. https:\/\/doi.org\/10.1002\/syn.20114","journal-title":"Synapse"},{"key":"1349_CR159","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2017.53.4.2604174","author":"DM Paton","year":"2017","unstructured":"Paton DM (2017) Crisaborole: phosphodiesterase inhibitor for treatment of atopic dermatitis. Drugs of Today. https:\/\/doi.org\/10.1358\/dot.2017.53.4.2604174","journal-title":"Drugs of Today"},{"key":"1349_CR160","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.13162","author":"V Pauwelyn","year":"2018","unstructured":"Pauwelyn V, Ceelen W, Lefebvre RA (2018) Synergy between 5-HT4 receptor stimulation and phosphodiesterase 4 inhibition in facilitating acetylcholine release in human large intestinal circular muscle. Neurogastroenterol Motil. https:\/\/doi.org\/10.1111\/nmo.13162","journal-title":"Neurogastroenterol Motil"},{"key":"1349_CR161","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3390\/ijms11010222","volume":"11","author":"S Peng","year":"2010","unstructured":"Peng S, Zhang Y, Zhang J et al (2010) ERK in learning and memory: a review of recent research. Int J Mol Sci 11:222\u2013232. https:\/\/doi.org\/10.3390\/ijms11010222","journal-title":"Int J Mol Sci"},{"key":"1349_CR162","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S0891-0618(00)00097-1","volume":"20","author":"S P\u00e9rez-Torres","year":"2000","unstructured":"P\u00e9rez-Torres S, Mir\u00f3 X, Palacios JM et al (2000) Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and [3H]rolipram binding autoradiography: comparison with monkey and rat brain. J Chem Neuroanat 20:349\u2013374. https:\/\/doi.org\/10.1016\/S0891-0618(00)00097-1","journal-title":"J Chem Neuroanat"},{"key":"1349_CR163","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1476-5381.2010.01035.x","volume":"162","author":"D Peter","year":"2011","unstructured":"Peter D, G\u00f6ggel R, Colbatzky F, Nickolaus P (2011) Inhibition of cyclooxygenase-2 prevents adverse effects induced by phosphodiesterase type 4 inhibitors in rats. Br J Pharmacol 162:415\u2013427. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.01035.x","journal-title":"Br J Pharmacol"},{"key":"1349_CR164","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1468-1331.2008.02056.x","volume":"15","author":"W Poewe","year":"2008","unstructured":"Poewe W (2008) Non-motor symptoms in Parkinson\u2019s disease. Eur J Neurol 15:14\u201320. https:\/\/doi.org\/10.1111\/j.1468-1331.2008.02056.x","journal-title":"Eur J Neurol"},{"key":"1349_CR165","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.13","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM et al (2017) Parkinson disease. Nat Rev Dis Prim. https:\/\/doi.org\/10.1038\/nrdp.2017.13","journal-title":"Nat Rev Dis Prim"},{"key":"1349_CR166","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1080\/13543784.2017.1364360","volume":"26","author":"J Prickaerts","year":"2017","unstructured":"Prickaerts J, Heckman PRA, Blokland A (2017) Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer\u2019s disease. Expert Opin Investig Drugs 26:1033\u20131048. https:\/\/doi.org\/10.1080\/13543784.2017.1364360","journal-title":"Expert Opin Investig Drugs"},{"key":"1349_CR167","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/BF00501379","volume":"304","author":"J Puurunen","year":"1978","unstructured":"Puurunen J, L\u00fccke C, Schwabe U (1978) Effect of the phosphodiesterase inhibitor 4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711) on gastric secretion and gastric mucosal cyclic AMP. Naunyn Schmiedebergs Arch Pharmacol 304:69\u201375. https:\/\/doi.org\/10.1007\/BF00501379","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"1349_CR168","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M003327200","author":"W Qiu","year":"2000","unstructured":"Qiu W, Zhuang S, Von Lintig FC et al (2000) Cell type-specific regulation of B-Raf kinase by cAMP and 14\u20133-3 proteins. J Biol Chem. https:\/\/doi.org\/10.1074\/jbc.M003327200","journal-title":"J Biol Chem"},{"key":"1349_CR169","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.neuropharm.2011.05.010","volume":"61","author":"TF Rau","year":"2011","unstructured":"Rau TF, Kothiwal A, Zhang L et al (2011) Low dose methamphetamine mediates neuroprotection through a PI3K-AKT pathway. Neuropharmacology 61:677\u2013686. https:\/\/doi.org\/10.1016\/j.neuropharm.2011.05.010","journal-title":"Neuropharmacology"},{"key":"1349_CR170","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25041008","author":"NU Rehman","year":"2020","unstructured":"Rehman NU, Ansari MN, Samad A (2020) In silico, ex vivo and in vivo studies of roflumilast as a potential antidiarrheal and antispasmodic agent: inhibition of the PDE-4 enzyme and voltage-gated Ca++ ion channels. Molecules. https:\/\/doi.org\/10.3390\/molecules25041008","journal-title":"Molecules"},{"key":"1349_CR171","doi-asserted-by":"publisher","DOI":"10.1097\/nen.0b013e3181567c31","author":"E Reyes-Irisarri","year":"2007","unstructured":"Reyes-Irisarri E, S\u00e1nchez AJ, Garc\u00eda-Merino JA, Mengod G (2007) Selective induction of cAMP phosphodiesterase PDE4B2 expression in experimental autoimmune encephalomyelitis. J Neuropathol Exp Neurol. https:\/\/doi.org\/10.1097\/nen.0b013e3181567c31","journal-title":"J Neuropathol Exp Neurol"},{"key":"1349_CR172","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3904\/kjim.2020.035","volume":"35","author":"CK Rhee","year":"2020","unstructured":"Rhee CK, Kim DK (2020) Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease. Korean J Intern Med 35:276\u2013283. https:\/\/doi.org\/10.3904\/kjim.2020.035","journal-title":"Korean J Intern Med"},{"key":"1349_CR173","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M203585200","author":"W Richter","year":"2002","unstructured":"Richter W, Conti M (2002) Dimerization of the type 4 cAMP-specific phosphodiesterases is mediated by the upstream conserved regions (UCRs). J Biol Chem. https:\/\/doi.org\/10.1074\/jbc.M203585200","journal-title":"J Biol Chem"},{"key":"1349_CR174","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M312687200","author":"W Richter","year":"2004","unstructured":"Richter W, Conti M (2004) The oligomerization state determines regulatory properties and inhibitor sensitivity of type 4 cAMP-specific phosphodiesterases. J Biol Chem. https:\/\/doi.org\/10.1074\/jbc.M312687200","journal-title":"J Biol Chem"},{"key":"1349_CR175","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0028-3908(00)00142-8","volume":"40","author":"A Robichaud","year":"2001","unstructured":"Robichaud A, Savoie C, Stamatiou PB et al (2001) PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. Neuropharmacology 40:262\u2013269. https:\/\/doi.org\/10.1016\/S0028-3908(00)00142-8","journal-title":"Neuropharmacology"},{"key":"1349_CR176","doi-asserted-by":"publisher","DOI":"10.1172\/jci200215506","author":"A Robichaud","year":"2002","unstructured":"Robichaud A, Stamatiou PB, Jin S-LC et al (2002) Deletion of phosphodiesterase 4D in mice shortens \u03b12-adrenoceptor\u2013mediated anesthesia, a behavioral correlate of emesis. J Clin Invest. https:\/\/doi.org\/10.1172\/jci200215506","journal-title":"J Clin Invest"},{"key":"1349_CR177","unstructured":"Roflumilast U.S. approval D (2011) DALIRESP\u00ae (roflumilast) tablets Initial U.S. Approval: 2011,. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/022522s009lbl.pdf"},{"key":"1349_CR178","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/07853890310016324","volume":"36","author":"P Roos-Mattjus","year":"2004","unstructured":"Roos-Mattjus P, Sistonen L (2004) The ubiquitin-proteasome pathway. Ann Med 36:285\u2013295. https:\/\/doi.org\/10.1080\/07853890310016324","journal-title":"Ann Med"},{"key":"1349_CR179","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.4103\/1673-5374.257523","volume":"14","author":"I Russo","year":"2019","unstructured":"Russo I (2019) The role of LRRK2 on PKA-NF\u03baB pathway in microglia cells: implications for Parkinson\u2019s disease. Neural Regen Res 14:1713. https:\/\/doi.org\/10.4103\/1673-5374.257523","journal-title":"Neural Regen Res"},{"key":"1349_CR180","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1742-2094-11-52","volume":"11","author":"I Russo","year":"2014","unstructured":"Russo I, Bubacco L, Greggio E (2014) LRRK2 and neuroinflammation: partners in crime in Parkinson\u2019s disease? J Neuroinflammation 11:52. https:\/\/doi.org\/10.1186\/1742-2094-11-52","journal-title":"J Neuroinflammation"},{"key":"1349_CR181","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12974-018-1337-8","volume":"15","author":"I Russo","year":"2018","unstructured":"Russo I, Di Benedetto G, Kaganovich A et al (2018) Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4. J Neuroinflammation 15:297. https:\/\/doi.org\/10.1186\/s12974-018-1337-8","journal-title":"J Neuroinflammation"},{"key":"1349_CR182","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005701","author":"A Sandebring","year":"2009","unstructured":"Sandebring A, Thomas KJ, Beilina A et al (2009) Mitochondrial alterations in PINK1 deficient cells are influenced by calcineurin-dependent dephosphorylation of dynamin-related protein 1. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0005701","journal-title":"PLoS ONE"},{"key":"1349_CR183","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-020-00787-3","author":"P Saroj","year":"2021","unstructured":"Saroj P, Bansal Y, Singh R et al (2021) Neuroprotective effects of roflumilast against quinolinic acid-induced rat model of Huntington\u2019s disease through inhibition of NF-\u03baB mediated neuroinflammatory markers and activation of cAMP\/CREB\/BDNF signaling pathway. Inflammopharmacology. https:\/\/doi.org\/10.1007\/s10787-020-00787-3","journal-title":"Inflammopharmacology"},{"key":"1349_CR184","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00559.x","author":"PH Schafer","year":"2010","unstructured":"Schafer PH, Parton A, Gandhi AK et al (2010) Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00559.x","journal-title":"Br J Pharmacol"},{"issue":"1","key":"1349_CR185","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1146\/annurev.med.50.1.57","volume":"50","author":"AL Schwartz","year":"1999","unstructured":"Schwartz AL, Ciechanover A (1999) The ubiquitin-proteasome pathway and pathogenesis of human diseases. Ann Rev Med 50(1):57\u201374. https:\/\/doi.org\/10.1146\/annurev.med.50.1.57","journal-title":"Ann Rev Med"},{"key":"1349_CR186","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182019","author":"J Schwenkgrub","year":"2017","unstructured":"Schwenkgrub J, Zaremba M, Joniec-Maciejak I et al (2017) The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson\u2019s disease. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0182019","journal-title":"PLoS ONE"},{"key":"1349_CR187","doi-asserted-by":"publisher","DOI":"10.1021\/bi800699v","author":"D Sevlever","year":"2008","unstructured":"Sevlever D, Jiang P, Yen SHC (2008) Cathepsin D is the main lysosomal enzyme involved in the degradation of \u03b1-synuclein and generation of its carboxy-terminally truncated species. Biochemistry. https:\/\/doi.org\/10.1021\/bi800699v","journal-title":"Biochemistry"},{"key":"1349_CR188","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1042\/BJ20021082","volume":"370","author":"M Shepherd","year":"2003","unstructured":"Shepherd M, McSorley T, Olsen AE et al (2003) Molecular cloning and subcellular distribution of the novel PDE4B4 cAMP-specific phosphodiesterase isoform. Biochem J 370:429\u2013438. https:\/\/doi.org\/10.1042\/BJ20021082","journal-title":"Biochem J"},{"key":"1349_CR189","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.9.3.959-964.1989","author":"F Shirakawa","year":"1989","unstructured":"Shirakawa F, Chedid M, Suttles J et al (1989) Interleukin 1 and cyclic AMP induce kappa immunoglobulin light-chain expression via activation of an NF-kappa B-like DNA-binding protein. Mol Cell Biol. https:\/\/doi.org\/10.1128\/mcb.9.3.959-964.1989","journal-title":"Mol Cell Biol"},{"key":"1349_CR190","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00237","author":"CR Sims","year":"2017","unstructured":"Sims CR, Singh SP, Mu S et al (2017) Rolipram improves outcome in a rat model of infant sepsis-induced cardiorenal syndrome. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2017.00237","journal-title":"Front Pharmacol"},{"key":"1349_CR191","doi-asserted-by":"publisher","DOI":"10.1186\/s12868-017-0364-1","author":"P Singh","year":"2017","unstructured":"Singh P, Hanson PS, Morris CM (2017) SIRT1 ameliorates oxidative stress induced neural cell death and is down-regulated in Parkinson\u2019s disease. BMC Neurosci. https:\/\/doi.org\/10.1186\/s12868-017-0364-1","journal-title":"BMC Neurosci"},{"key":"1349_CR192","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1080\/17425247.2020.1779218","volume":"17","author":"P Sola","year":"2020","unstructured":"Sola P, Krishnamurthy P, Chintamaneni PK et al (2020) Novel drug delivery systems of \u03b22 adrenoreceptor agonists to suppress SNCA gene expression and mitochondrial oxidative stress in Parkinson\u2019s disease management. Expert Opin Drug Deliv 17:1119\u20131132. https:\/\/doi.org\/10.1080\/17425247.2020.1779218","journal-title":"Expert Opin Drug Deliv"},{"key":"1349_CR193","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/bjp.2008.307","volume":"155","author":"D Spina","year":"2008","unstructured":"Spina D (2008) PDE4 inhibitors: current status. Br J Pharmacol 155:308\u2013315. https:\/\/doi.org\/10.1038\/bjp.2008.307","journal-title":"Br J Pharmacol"},{"key":"1349_CR194","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-016-0288-2","author":"P Srivastava","year":"2018","unstructured":"Srivastava P, Dhuriya YK, Gupta R et al (2018) Protective effect of curcumin by modulating BDNF\/DARPP32\/CREB in arsenic-induced alterations in dopaminergic signaling in rat corpus striatum. Mol Neurobiol. https:\/\/doi.org\/10.1007\/s12035-016-0288-2","journal-title":"Mol Neurobiol"},{"key":"1349_CR195","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/nature06994","volume":"453","author":"A Stipanovich","year":"2008","unstructured":"Stipanovich A, Valjent E, Matamales M et al (2008) A phosphatase cascade by which rewarding stimuli control nucleosomal response. Nature 453:879\u2013884. https:\/\/doi.org\/10.1038\/nature06994","journal-title":"Nature"},{"key":"1349_CR196","doi-asserted-by":"publisher","DOI":"10.1016\/S0898-6568(99)00037-6","author":"M Sullivan","year":"1999","unstructured":"Sullivan M, Olsen AS, Houslay MD (1999) Genomic organisation of the human cyclic AMP-specific phosphodiesterase PDE4C gene and its chromosomal localisation to 19p13.1, between RAB3A and JUND. Cell Signal. https:\/\/doi.org\/10.1016\/S0898-6568(99)00037-6","journal-title":"Cell Signal"},{"key":"1349_CR197","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.it.2013.01.004","volume":"34","author":"S-C Sun","year":"2013","unstructured":"Sun S-C, Chang J-H, Jin J (2013) Regulation of nuclear factor-\u03baB in autoimmunity. Trends Immunol 34:282\u2013289. https:\/\/doi.org\/10.1016\/j.it.2013.01.004","journal-title":"Trends Immunol"},{"key":"1349_CR198","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1254\/jphs.13103FP","volume":"123","author":"O Suzuki","year":"2013","unstructured":"Suzuki O, Mizukami K, Etori M et al (2013) Evaluation of the therapeutic index of a novel phosphodiesterase 4B - selective inhibitor over phosphodiesterase 4D in mice. J Pharmacol Sci 123:219\u2013226. https:\/\/doi.org\/10.1254\/jphs.13103FP","journal-title":"J Pharmacol Sci"},{"key":"1349_CR199","doi-asserted-by":"publisher","DOI":"10.1126\/science.1089681","author":"P Svenningsson","year":"2003","unstructured":"Svenningsson P, Tzavara ET, Carruthers R et al (2003) Diverse psychotomimetics act through a common signaling pathway. Science. https:\/\/doi.org\/10.1126\/science.1089681","journal-title":"Science"},{"key":"1349_CR200","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.14.5325","author":"JV Swinnen","year":"1989","unstructured":"Swinnen JV, Joseph DR, Conti M (1989) Molecular cloning of rat homologues of the drosophila melanogaster dunce cAMP phosphodiesterase: evidence for a family of genes. Proc Natl Acad Sci USA. https:\/\/doi.org\/10.1073\/pnas.86.14.5325","journal-title":"Proc Natl Acad Sci USA"},{"key":"1349_CR201","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1523\/jneurosci.19-02-00610.1999","volume":"19","author":"M Takahashi","year":"1999","unstructured":"Takahashi M, Terwilliger R, Lane C et al (1999) Chronic antidepressant administration increases the expression of cAMP- specific phosphodiesterase 4A and 4B isoforms. J Neurosci 19:610\u2013618. https:\/\/doi.org\/10.1523\/jneurosci.19-02-00610.1999","journal-title":"J Neurosci"},{"key":"1349_CR202","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s11307-018-1168-0","volume":"20","author":"A Takano","year":"2018","unstructured":"Takano A, Uz T, Garcia-Segovia J et al (2018) A Nonhuman primate PET study: measurement of brain PDE4 occupancy by roflumilast using (R)-[11C]Rolipram. Mol Imaging Biol 20:615\u2013622. https:\/\/doi.org\/10.1007\/s11307-018-1168-0","journal-title":"Mol Imaging Biol"},{"key":"1349_CR203","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704146","author":"K Takuma","year":"2001","unstructured":"Takuma K, Lee E, Enomoto R et al (2001) Ibudilast attenuates astrocyte apoptosis via cyclic GMP signalling pathway in an in vitro reperfusion model. Br J Pharmacol. https:\/\/doi.org\/10.1038\/sj.bjp.0704146","journal-title":"Br J Pharmacol"},{"key":"1349_CR204","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M407389200","author":"TS Tang","year":"2004","unstructured":"Tang TS, Bezprozvaany I (2004) Dopamine receptor-mediated Ca2+ signaling in striatal medium spiny neurons. J Biol Chem. https:\/\/doi.org\/10.1074\/jbc.M407389200","journal-title":"J Biol Chem"},{"key":"1349_CR205","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ejmech.2019.02.026","volume":"168","author":"L Tang","year":"2019","unstructured":"Tang L, Huang C, Zhong J et al (2019) Discovery of arylbenzylamines as PDE4 inhibitors with potential neuroprotective effect. Eur J Med Chem 168:221\u2013231. https:\/\/doi.org\/10.1016\/j.ejmech.2019.02.026","journal-title":"Eur J Med Chem"},{"key":"1349_CR206","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.nbd.2009.11.004","volume":"37","author":"MG Tansey","year":"2010","unstructured":"Tansey MG, Goldberg MS (2010) Neuroinflammation in Parkinson\u2019s disease: Its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37:510\u2013518. https:\/\/doi.org\/10.1016\/j.nbd.2009.11.004","journal-title":"Neurobiol Dis"},{"key":"1349_CR207","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1517\/14656566.2013.837159","volume":"15","author":"DP Tashkin","year":"2014","unstructured":"Tashkin DP (2014) Roflumilast: the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD. Expert Opin Pharmacother 15:85\u201396. https:\/\/doi.org\/10.1517\/14656566.2013.837159","journal-title":"Expert Opin Pharmacother"},{"key":"1349_CR208","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/brain\/109.5.845","volume":"109","author":"AE Taylor","year":"1986","unstructured":"Taylor AE, Saint-cyr JA, Lang AE (1986) Frontal lobe dysfunction in parkinson\u2019s disease: the cortical focus of neostriatal outflow. Brain 109:845\u2013883. https:\/\/doi.org\/10.1093\/brain\/109.5.845","journal-title":"Brain"},{"key":"1349_CR209","unstructured":"Tetra Discovery Partners (2016) Tetra Discovery Partners Announces Positive Results from Phase 1 Studies of Cognition Drug Candidate, BPN14770. 0\u20132. https:\/\/tetratherapeutics.com\/wp-content\/uploads\/2016\/11\/FINAL-Tetra-Phase-1-121616-FINAL.pdf"},{"key":"1349_CR210","doi-asserted-by":"publisher","DOI":"10.1042\/BST20190763","author":"AJ Tibbo","year":"2019","unstructured":"Tibbo AJ, Tejeda GS, Baillie GS (2019) Understanding PDE4\u2019s function in Alzheimer\u2019s disease A target for novel therapeutic approaches. Biochem Soc Trans. https:\/\/doi.org\/10.1042\/BST20190763","journal-title":"Biochem Soc Trans"},{"key":"1349_CR211","doi-asserted-by":"publisher","DOI":"10.2174\/1381612820666140826113731","author":"D Titus","year":"2014","unstructured":"Titus D, Oliva A, Wilson N, Atkins C (2014) Phosphodiesterase inhibitors as therapeutics for traumatic brain injury. Curr Pharm Des. https:\/\/doi.org\/10.2174\/1381612820666140826113731","journal-title":"Curr Pharm Des"},{"key":"1349_CR212","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.nlm.2017.12.008","volume":"148","author":"DJ Titus","year":"2018","unstructured":"Titus DJ, Wilson NM, Alcazar O et al (2018) A negative allosteric modulator of PDE4D enhances learning after traumatic brain injury. Neurobiol Learn Mem 148:38\u201349. https:\/\/doi.org\/10.1016\/j.nlm.2017.12.008","journal-title":"Neurobiol Learn Mem"},{"key":"1349_CR213","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M308041200","author":"GK Tofaris","year":"2003","unstructured":"Tofaris GK, Razzaq A, Ghetti B et al (2003) Ubiquitination of \u03b1-synuclein in lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem. https:\/\/doi.org\/10.1074\/jbc.M308041200","journal-title":"J Biol Chem"},{"key":"1349_CR214","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2018.00165","author":"H Tong","year":"2018","unstructured":"Tong H, Zhang X, Meng X et al (2018) Simvastatin inhibits activation of nadph oxidase\/p38 MAPK pathway and enhances expression of antioxidant protein in parkinson disease models. Front Mol Neurosci. https:\/\/doi.org\/10.3389\/fnmol.2018.00165","journal-title":"Front Mol Neurosci"},{"key":"1349_CR215","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1006\/pupt.1999.0181","volume":"12","author":"TJ Torphy","year":"1999","unstructured":"Torphy TJ, Barnette MS, Underwood DC et al (1999) ArifloTM(SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol Ther 12:131\u2013135. https:\/\/doi.org\/10.1006\/pupt.1999.0181","journal-title":"Pulm Pharmacol Ther"},{"key":"1349_CR216","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00860","author":"P Troncoso-Escudero","year":"2018","unstructured":"Troncoso-Escudero P, Parra A, Nassif M, Vidal RL (2018) Outside in: unraveling the role of neuroinflammation in the progression of Parkinson\u2019s disease. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2018.00860","journal-title":"Front Neurol"},{"key":"1349_CR217","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","volume":"124","author":"O-B Tysnes","year":"2017","unstructured":"Tysnes O-B, Storstein A (2017) Epidemiology of Parkinson\u2019s disease. J Neural Transm 124:901\u2013905. https:\/\/doi.org\/10.1007\/s00702-017-1686-y","journal-title":"J Neural Transm"},{"key":"1349_CR218","doi-asserted-by":"publisher","DOI":"10.1021\/bi00476a001","author":"BL Vallee","year":"1990","unstructured":"Vallee BL, Auld DS (1990) Zinc coordination, function, and structure of zinc enzymes and other proteins. Biochemistry. https:\/\/doi.org\/10.1021\/bi00476a001","journal-title":"Biochemistry"},{"key":"1349_CR219","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1042\/BCJ20160809","volume":"474","author":"JJS VerPlank","year":"2017","unstructured":"VerPlank JJS, Goldberg AL (2017) Regulating protein breakdown through proteasome phosphorylation. Biochem J 474:3355\u20133371. https:\/\/doi.org\/10.1042\/BCJ20160809","journal-title":"Biochem J"},{"key":"1349_CR220","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.2001.7651","author":"DM Vogt Weisenhorn","year":"2001","unstructured":"Vogt Weisenhorn DM, Roback LJ, Kwon JH, Wainer BH (2001) Coupling of cAMP\/PKA and MAPK signaling in neuronal cells is dependent on developmental stage. Exp Neurol. https:\/\/doi.org\/10.1006\/exnr.2001.7651","journal-title":"Exp Neurol"},{"key":"1349_CR221","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/BF00432761","volume":"77","author":"H Wachtel","year":"1982","unstructured":"Wachtel H (1982) Characteristic behavioral alterations in rats induced by rolipram and other selective adenosine cyclic 3\u2032,5\u2032-monophosphate phosphodiesterase inhibitors. Psychopharmacology 77:309\u2013316. https:\/\/doi.org\/10.1007\/BF00432761","journal-title":"Psychopharmacology"},{"key":"1349_CR222","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/j.2042-7158.1983.tb04318.x","volume":"35","author":"H Wachtel","year":"1983","unstructured":"Wachtel H (1983) Neurotropic effects of the optical isomers of the selective adenosine cyclic 3\u2032,5\u2032-monophosphate phosphodiesterase inhibitor rolipram in rats in-vivo. J Pharm Pharmacol 35:440\u2013444. https:\/\/doi.org\/10.1111\/j.2042-7158.1983.tb04318.x","journal-title":"J Pharm Pharmacol"},{"key":"1349_CR223","doi-asserted-by":"publisher","DOI":"10.1124\/mol.56.1.170","author":"P Wang","year":"1999","unstructured":"Wang P, Wu P, Ohleth KM et al (1999) Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol Pharmacol. https:\/\/doi.org\/10.1124\/mol.56.1.170","journal-title":"Mol Pharmacol"},{"key":"1349_CR224","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1093\/hmg\/ddi413","volume":"14","author":"C Wang","year":"2005","unstructured":"Wang C, Ko HS, Thomas B et al (2005) Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin\u2019s protective function. Hum Mol Genet 14:3885\u20133897. https:\/\/doi.org\/10.1093\/hmg\/ddi413","journal-title":"Hum Mol Genet"},{"key":"1349_CR225","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2006.02.012","author":"XF Wang","year":"2006","unstructured":"Wang XF, Li S, Chou AP, Bronstein JM (2006) Inhibitory effects of pesticides on proteasome activity: implication in Parkinson\u2019s disease. Neurobiol Dis. https:\/\/doi.org\/10.1016\/j.nbd.2006.02.012","journal-title":"Neurobiol Dis"},{"key":"1349_CR226","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20070970","author":"H Wang","year":"2007","unstructured":"Wang H, Peng MS, Chen Y et al (2007) Structures of the four subfamilies of phosphodiesterases provide insight into the selectivity of their inhibitors. Biochem J. https:\/\/doi.org\/10.1042\/BJ20070970","journal-title":"Biochem J"},{"key":"1349_CR227","doi-asserted-by":"publisher","first-page":"17380","DOI":"10.18632\/oncotarget.8041","volume":"7","author":"G Wang","year":"2016","unstructured":"Wang G, Chen L, Pan X et al (2016) The effect of resveratrol on beta amyloid-induced memory impairment involves inhibition of phosphodiesterase-4 related signaling. Oncotarget 7:17380\u201317392. https:\/\/doi.org\/10.18632\/oncotarget.8041","journal-title":"Oncotarget"},{"key":"1349_CR228","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2018.00255","author":"H Wang","year":"2018","unstructured":"Wang H, Xu J, Lazarovici P et al (2018) cAMP response element-binding protein (CREB): a possible signaling molecule link in the pathophysiology of schizophrenia. Front Mol Neurosci. https:\/\/doi.org\/10.3389\/fnmol.2018.00255","journal-title":"Front Mol Neurosci"},{"key":"1349_CR229","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2020.101427","author":"Z Wang","year":"2020","unstructured":"Wang Z, Dong H, Wang J et al (2020) Pro-survival and anti-inflammatory roles of NF-\u03baB c-Rel in the Parkinson\u2019s disease models. Redox Biol. https:\/\/doi.org\/10.1016\/j.redox.2020.101427","journal-title":"Redox Biol"},{"key":"1349_CR230","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/j.1750-3639.2010.00373.x","volume":"20","author":"GS Watson","year":"2010","unstructured":"Watson GS, Leverenz JB (2010) Profile of cognitive impairment in Parkinson\u2019s disease. Brain Pathol 20:640\u2013645. https:\/\/doi.org\/10.1111\/j.1750-3639.2010.00373.x","journal-title":"Brain Pathol"},{"key":"1349_CR231","doi-asserted-by":"publisher","DOI":"10.1021\/cr950043b","author":"DE Wilcox","year":"1996","unstructured":"Wilcox DE (1996) Binuclear metallohydrolases. Chem Rev. https:\/\/doi.org\/10.1021\/cr950043b","journal-title":"Chem Rev"},{"key":"1349_CR232","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2019.02.027","author":"H Wilson","year":"2020","unstructured":"Wilson H, Pagano G, Niccolini F et al (2020) The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson\u2019s disease. Park Relat Disord. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.02.027","journal-title":"Park Relat Disord"},{"key":"1349_CR233","doi-asserted-by":"publisher","DOI":"10.1159\/000328516","author":"Y Wu","year":"2011","unstructured":"Wu Y, Li X, Zhu JX et al (2011) Resveratrol-activated AMPK\/SIRT1\/autophagy in cellular models of Parkinson\u2019s disease. Neurosignals. https:\/\/doi.org\/10.1159\/000328516","journal-title":"Neurosignals"},{"key":"1349_CR234","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1021\/acschemneuro.1c00762","volume":"13","author":"C Xia","year":"2022","unstructured":"Xia C, He JP, Feng KW et al (2022) Discovery of novel 3-Amino-4-alkoxyphenylketones as PDE4 inhibitors with improved oral bioavailability and safety against spatial memory impairments. ACS Chem Neurosci 13:390\u2013405","journal-title":"ACS Chem Neurosci"},{"key":"1349_CR235","doi-asserted-by":"publisher","DOI":"10.1126\/science.288.5472.1822","author":"RX Xu","year":"2000","unstructured":"Xu RX, Hassell AM, Vanderwall D et al (2000) Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science. https:\/\/doi.org\/10.1126\/science.288.5472.1822","journal-title":"Science"},{"key":"1349_CR236","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2019.02.023","author":"B Xu","year":"2019","unstructured":"Xu B, Wang T, Xiao J et al (2019) FCPR03, a novel phosphodiesterase 4 inhibitor, alleviates cerebral ischemia\/reperfusion injury through activation of the AKT\/GSK3\u03b2\/ \u03b2-catenin signaling pathway. Biochem Pharmacol. https:\/\/doi.org\/10.1016\/j.bcp.2019.02.023","journal-title":"Biochem Pharmacol"},{"key":"1349_CR237","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s12576-016-0445-4","volume":"66","author":"K Yamada","year":"2016","unstructured":"Yamada K, Takahashi S, Karube F et al (2016) Neuronal circuits and physiological roles of the basal ganglia in terms of transmitters, receptors and related disorders. J Physiol Sci 66:435\u2013446. https:\/\/doi.org\/10.1007\/s12576-016-0445-4","journal-title":"J Physiol Sci"},{"key":"1349_CR238","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2019.110743","author":"T Yan","year":"2019","unstructured":"Yan T, Sun Y, Gong G et al (2019) The neuroprotective effect of schisandrol A on 6-OHDA-induced PD mice may be related to PI3K\/AKT and IKK\/I\u03baB\u03b1\/NF-\u03baB pathway. Exp Gerontol. https:\/\/doi.org\/10.1016\/j.exger.2019.110743","journal-title":"Exp Gerontol"},{"key":"1349_CR239","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2007.02.010","author":"L Yang","year":"2008","unstructured":"Yang L, Calingasan NY, Lorenzo BJ, Beal MF (2008) Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV. Exp Neurol. https:\/\/doi.org\/10.1016\/j.expneurol.2007.02.010","journal-title":"Exp Neurol"},{"key":"1349_CR240","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2018.00073","author":"L Yang","year":"2018","unstructured":"Yang L, Wang H, Liu L, Xie A (2018) The role of insulin\/IGF-1\/PI3K\/Akt\/GSK3\u03b2 signaling in Parkinson\u2019s disease dementia. Front Neurosci. https:\/\/doi.org\/10.3389\/fnins.2018.00073","journal-title":"Front Neurosci"},{"key":"1349_CR241","doi-asserted-by":"publisher","unstructured":"Yger M, Girault JA (2011) DARPP-32, jack of all trades...master of which? Front Behav Neurosci, Doi: https:\/\/doi.org\/10.3389\/fnbeh.2011.00056","DOI":"10.3389\/fnbeh.2011.00056"},{"key":"1349_CR242","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M308484200","author":"W Yin","year":"2003","unstructured":"Yin W, Mu J, Birnbaum MJ (2003) Role of AMP-activated protein kinase in cyclic AMP-dependent lipolysis in 3T3-L1 adipocytes. J Biol Chem. https:\/\/doi.org\/10.1074\/jbc.M308484200","journal-title":"J Biol Chem"},{"key":"1349_CR243","doi-asserted-by":"publisher","DOI":"10.1002\/2327-6924.12428","author":"M Young","year":"2016","unstructured":"Young M, Roebuck HL (2016) Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: a novel treatment option for nurse practitioners treating patients with psoriatic disease. J Am Assoc Nurse Pract. https:\/\/doi.org\/10.1002\/2327-6924.12428","journal-title":"J Am Assoc Nurse Pract"},{"key":"1349_CR244","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1038\/mt.2016.175","volume":"24","author":"S Yu","year":"2016","unstructured":"Yu S, Pearson AD, Lim RKV et al (2016) Targeted delivery of an anti-inflammatory PDE4 inhibitor to immune cells via an antibody-drug conjugate. Mol Ther 24:2078\u20132089. https:\/\/doi.org\/10.1038\/mt.2016.175","journal-title":"Mol Ther"},{"key":"1349_CR245","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s12264-010-0302-z","volume":"26","author":"H Yuan","year":"2010","unstructured":"Yuan H, Zhang Z-W, Liang L-W et al (2010) Treatment strategies for Parkinson\u2019s disease. Neurosci Bull 26:66\u201376. https:\/\/doi.org\/10.1007\/s12264-010-0302-z","journal-title":"Neurosci Bull"},{"key":"1349_CR246","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00016","author":"NN Yuan","year":"2019","unstructured":"Yuan NN, Cai CZ, JmY Wu et al (2019) Canthin-6-one accelerates alpha-synuclein degradation by enhancing UPS activity: drug target identification by CRISPR-Cas9 whole genome-wide screening technology. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2019.00016","journal-title":"Front Pharmacol"},{"key":"1349_CR247","doi-asserted-by":"publisher","DOI":"10.2174\/138161209788168092","author":"H-T Zhang","year":"2009","unstructured":"Zhang H-T (2009) Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs. Curr Pharm Des. https:\/\/doi.org\/10.2174\/138161209788168092","journal-title":"Curr Pharm Des"},{"key":"1349_CR248","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/sj.cr.7290105","volume":"12","author":"W Zhang","year":"2002","unstructured":"Zhang W, Liu HT (2002) MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 12:9\u201318. https:\/\/doi.org\/10.1038\/sj.cr.7290105","journal-title":"Cell Res"},{"key":"1349_CR249","doi-asserted-by":"publisher","DOI":"10.1007\/s40520-015-0472-7","author":"Y Zhong","year":"2016","unstructured":"Zhong Y, Chen AF, Zhao J et al (2016) Serum levels of cathepsin D, sirtuin1, and endothelial nitric oxide synthase are correlatively reduced in elderly healthy people. Aging Clin Exp Res. https:\/\/doi.org\/10.1007\/s40520-015-0472-7","journal-title":"Aging Clin Exp Res"},{"key":"1349_CR250","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2018.02.008","author":"J Zhong","year":"2018","unstructured":"Zhong J, Yu H, Huang C et al (2018) Inhibition of phosphodiesterase 4 by FCPR16 protects SH-SY5Y cells against MPP+-induced decline of mitochondrial membrane potential and oxidative stress. Redox Biol. https:\/\/doi.org\/10.1016\/j.redox.2018.02.008","journal-title":"Redox Biol"},{"key":"1349_CR251","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2019.02.027","author":"J Zhong","year":"2019","unstructured":"Zhong J, Xie J, Xiao J et al (2019) Inhibition of PDE4 by FCPR16 induces AMPK-dependent autophagy and confers neuroprotection in SH-SY5Y cells and neurons exposed to MPP + -induced oxidative insult. Free Radic Biol Med. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2019.02.027","journal-title":"Free Radic Biol Med"},{"key":"1349_CR252","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14983","author":"J Zhong","year":"2020","unstructured":"Zhong J, Dong W, Qin Y et al (2020) Roflupram exerts neuroprotection via activation of CREB\/PGC-1\u03b1 signalling in experimental models of Parkinson\u2019s disease. Br J Pharmacol. https:\/\/doi.org\/10.1111\/bph.14983","journal-title":"Br J Pharmacol"},{"key":"1349_CR253","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2021.115859","author":"J Zhong","year":"2022","unstructured":"Zhong J, Li M, Xu J et al (2022) Roflupram attenuates \u03b1-synuclein-induced cytotoxicity and promotes the mitochondrial translocation of Parkin in SH-SY5Y cells overexpressing A53T mutant \u03b1-synuclein. Toxicol Appl Pharmacol. https:\/\/doi.org\/10.1016\/j.taap.2021.115859","journal-title":"Toxicol Appl Pharmacol"},{"key":"1349_CR254","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2016.08.007","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Wu Z, Cao X et al (2016a) HNO suppresses LPS-induced inflammation in BV-2 microglial cells via inhibition of NF-\u03baB and p38 MAPK pathways. Pharmacol Res. https:\/\/doi.org\/10.1016\/j.phrs.2016.08.007","journal-title":"Pharmacol Res"},{"key":"1349_CR255","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.ejmech.2016.08.052","volume":"124","author":"ZZ Zhou","year":"2016","unstructured":"Zhou ZZ, Ge BC, Zhong QP et al (2016b) Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings. Eur J Med Chem 124:372\u2013379. https:\/\/doi.org\/10.1016\/j.ejmech.2016.08.052","journal-title":"Eur J Med Chem"},{"key":"1349_CR256","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.2003.tb00478.x","author":"JH Zhu","year":"2003","unstructured":"Zhu JH, Guo F, Shelburne J et al (2003) Localization of phosphorylated ERK\/MAP kinases to mitochondria and autophagosomes in lewy body diseases. Brain Pathol. https:\/\/doi.org\/10.1111\/j.1750-3639.2003.tb00478.x","journal-title":"Brain Pathol"},{"key":"1349_CR257","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.116.239608","author":"ZQ Zou","year":"2017","unstructured":"Zou ZQ, Chen JJ, Feng HF et al (2017) Novel phosphodiesterase 4 inhibitor FCPR03 alleviates lipopolysaccharide-induced neuroinflammation by regulation of the cAMP\/PKA\/CREB signaling pathway and NF-\u03baB inhibition. J Pharmacol Exp Ther. https:\/\/doi.org\/10.1124\/jpet.116.239608","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Cellular and Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10571-023-01349-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10571-023-01349-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10571-023-01349-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T16:18:14Z","timestamp":1689005894000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10571-023-01349-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":257,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1349"],"URL":"https:\/\/doi.org\/10.1007\/s10571-023-01349-1","relation":{},"ISSN":["0272-4340","1573-6830"],"issn-type":[{"value":"0272-4340","type":"print"},{"value":"1573-6830","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,19]]},"assertion":[{"value":"18 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}